Original Article
Calcium plus Vitamin D Supplementation and the Risk of Fractures
N Engl J Med 2006; 354:669-683February 16, 2006
- Abstract
Background
The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal.
Methods
We recruited 36,282 postmenopausal women, 50 to 79 years of age, who were already enrolled in a Women's Health Initiative (WHI) clinical trial. We randomly assigned participants to receive 1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily or placebo. Fractures were ascertained for an average follow-up period of 7.0 years. Bone density was measured at three WHI centers.
Results
Hip bone density was 1.06 percent higher in the calcium plus vitamin D group than in the placebo group (P<0.01). Intention-to-treat analysis indicated that participants receiving calcium plus vitamin D supplementation had a hazard ratio of 0.88 for hip fracture (95 percent confidence interval, 0.72 to 1.08), 0.90 for clinical spine fracture (0.74 to 1.10), and 0.96 for total fractures (0.91 to 1.02). The risk of renal calculi increased with calcium plus vitamin D (hazard ratio, 1.17; 95 percent confidence interval, 1.02 to 1.34). Censoring data from women when they ceased to adhere to the study medication reduced the hazard ratio for hip fracture to 0.71 (95 percent confidence interval, 0.52 to 0.97). Effects did not vary significantly according to prerandomization serum vitamin D levels.
Conclusions
Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones. (ClinicalTrials.gov number, NCT00000611.)
Media in This Article
Figure 1
Profile of the Calcium with Vitamin D Trial of the Women's Health Initiative (WHI).Figure 2
Hip, Spine, and Total-Body Bone Mineral Density (BMD).Article Activity
- Article
Osteoporosis, a major cause of injury, loss of independence, and death,1,2 contributes to more than 300,000 hip fractures in the United States annually.3 Observational evidence4 and data from randomized clinical trials5,6 suggest that calcium or vitamin D supplements or both may slow bone loss5,6 and reduce the risk of falls7,8 in postmenopausal and elderly women. However, evidence from trials,5,9-19 observational studies,20,21 and meta-analyses6,22,23 of calcium and vitamin D supplementation with respect to hip and other fractures is limited. In two recent randomized trials, calcium plus vitamin D supplements (1000 mg of calcium and 800 IU of vitamin D3) did not reduce the risk of nonvertebral fractures among older women.18,19 When the calcium plus vitamin D trial of the Women's Health Initiative (WHI) was designed, in the early 1990s, guidelines recommended daily intakes of 800 to 1200 mg of calcium with 400 IU of vitamin D for the prevention of osteoporosis. Many American women consumed less.
In this context, the WHI calcium with vitamin D trial was designed to test the primary hypothesis that postmenopausal women randomly assigned to calcium plus vitamin D supplementation would have a lower risk of hip fracture and, secondarily, of all fractures than women assigned to placebo.24 Another secondary hypothesis was that women receiving calcium with vitamin D supplementation would have a lower rate of colorectal cancer than those receiving placebo; the results of that investigation are reported elsewhere in this issue of the Journal.25
Methods
Participants and Study Design
Participants enrolled in the WHI Dietary Modification trial, WHI Hormone Therapy trials, or both were invited to join the calcium with vitamin D trial at their first or second annual follow-up visit. Detailed descriptions of the eligibility criteria and recruitment methods have been published previously.24
Eligible women were 50 to 79 years of age at the initial screening and had no evidence of a medical condition associated with a predicted survival of less than three years and no safety, adherence, or retention risks. Exclusion criteria included hypercalcemia, renal calculi, corticosteroid use, and calcitriol use. Personal supplemental calcium (up to 1000 mg per day) and vitamin D (up to 600 IU per day) were allowed. In 1999, after the publication of reports from the Institute of Medicine,26,27 the upper limit of personal vitamin D intake was raised to 1000 IU. The calcium with vitamin D trial permitted the use of bisphosphonates and calcitonin. Use of estrogen (with or without a progestin) was according to randomization among women in the Hormone Therapy trials. Independent use of hormone therapy or selective estrogen-receptor modulators was permitted for women in the Dietary Modification trial.
Eligible women were randomly assigned in a double-blind fashion to receive supplements or placebo (provided by GlaxoSmithKline) in equal proportions with use of a permuted-block algorithm stratified according to clinical center and age. Active tablets, chewable or swallowable (after July 1997), contained 500 mg of elemental calcium (as calcium carbonate) and 200 IU of vitamin D3. Participants were instructed to take two tablets per day in divided doses and with meals to maximize absorption. Cross-sectional comparison of 25-hydroxyvitamin D levels from 227 women taking active supplements and 221 women taking placebo two years after randomization revealed that the 25-hydroxyvitamin D level was 28 percent higher among the women assigned to active calcium plus vitamin D than among those assigned to placebo.
The protocol was approved by the institutional review board at each participating institution. Written informed consent was obtained from each woman at the calcium with vitamin D randomization visit. The WHI Investigators and National Institutes of Health sponsors all contributed to the design and execution of the study. All the authors contributed to drafts or revisions of the manuscript. Statistical analyses and data management were conducted at the WHI Clinical Coordinating Center, and the investigators and statistical team vouch for the completeness and veracity of the data and statistical analyses.
Follow-up and Data Collection
The presence and severity of symptoms, safety concerns, and outcomes were ascertained at annual clinic visits and telephone or clinic visits at intervening six-month intervals.24 Adherence to the study medication was established by weighing returned pill bottles during clinic visits. Participants were followed for major outcomes, regardless of their adherence to the study medication, until death, loss to follow-up, or study close-out. Risk factors for fracture were assessed by questionnaire, interview, and clinical examination. The total daily calcium intake before randomization was defined as the sum of the following: the dietary calcium intake (assessed with the use of a modification of the Block food-frequency questionnaire28), the intake of calcium from supplements in the previous two weeks, and the intake of calcium from prescription medications (assessed through an interviewer-administered medication survey). Total vitamin D intake was similarly determined on the basis of diet and supplement use.
Discontinuation of Study Medications
During the trial, intolerable gastrointestinal symptoms were managed without unblinding by reducing the number of times per day or days per week that the study medication was taken. If renal calculi or hypercalcemia developed or renal dialysis was required, calcium with vitamin D study medication was permanently discontinued, according to the protocol.
Ascertainment of Outcomes
Total fractures were defined as all reported clinical fractures other than those of the ribs, sternum, skull or face, fingers, toes, and cervical vertebrae. All included fractures were verified by review of radiologic, magnetic resonance imaging, or operative reports by centrally trained and blinded physician adjudicators at each clinical center.24 Final adjudication of hip fractures was performed centrally by blinded adjudicators; agreement between central and local adjudication was 94 percent.
A subgroup of 2431 women (1230 in the calcium with vitamin D group and 1201 in the placebo group) at 3 of the 40 clinical centers (Pittsburgh; Birmingham, Ala.; and Tucson, Ariz.) underwent dual-energy x-ray absorptiometry of the lumbar spine (L2, L3, and L4), total hip, and total body (QDR 2000, QDR 2000+, or QDR 4500W; Hologic). Bone mineral density was measured at the calcium with vitamin D randomization visit and at annual visits 3, 6, and 9 according to standard protocols.24 Three Hologic phantoms (spine, hip, and linearity) were exchanged among these three centers and measured in array mode five times, once each day for five consecutive days, to assess cross-calibration. Spine, hip, and linearity phantoms were in close agreement (interscanner variability, <1.5 percent for the spine, 4.8 percent for the hip, and 1.7 percent for linearity).
Analysis of Vitamin D Levels
Blood specimens, which were obtained after an overnight fast, were collected at the randomization visit. To determine whether the effect of calcium plus vitamin D on the risk of fracture varied according to prerandomization 25-hydroxyvitamin D levels, a nested case–control study was performed with all adjudicated cases of hip, spine, and lower arm or wrist fracture used as cases (357 case–control pairs for hip fracture and 1491 pairs for total fracture). Controls were free of fracture for the duration of the study and were individually matched to case participants according to age, latitude of the clinical center, race or ethnic group, and date of venipuncture. Levels of 25-hydroxyvitamin D were measured with the use of the DiaSorin Liaison chemiluminescent immunoassay system at DiaSorin headquarters (Stillwater, Minn.) in one continuous batch with blinded control runs at periodic intervals (coefficient of variation, 11.8 percent).
Statistical Analysis
All primary outcomes were analyzed on a time-to-event basis according to the intention-to-treat principle. We present both the total number of events and the annualized percentage for these fracture rates for each group. Comparisons are represented with hazard ratios and nominal 95 percent confidence intervals from Cox proportional-hazards models, stratified according to age group, prior fracture, and randomization status (randomly assigned to active hormone therapy or placebo, dietary intervention vs. dietary control, or both) in the Hormone Therapy and Dietary Modification trials.
To assess whether the effect of calcium with vitamin D on the risk of fracture varied according to baseline levels of risk factors, the same Cox proportional-hazards models were extended. In formal tests for interaction, continuous variables were used whenever possible. Fifteen participant characteristics were examined for each of four fracture outcomes. Up to three statistically significant interaction tests (P<0.05) would be expected on the basis of chance alone.
To examine the effect of nonadherence (to active supplements or placebo), sensitivity analyses were conducted in which participants were allowed to contribute follow-up time until six months after the first visit at which nonadherence, defined as use of less than 80 percent of the study medication, was detected. Full-adherence hazard ratios were also estimated with inverse probability of censoring weighted estimators with adjustment for 10 covariates associated with adherence.29
Changes in bone mineral density during follow-up were calculated as mean percent differences (and standard errors) from bone mineral density at the time of enrollment in the calcium plus vitamin D trial. Linear regression was used to compare rates of change in bone mineral density between the groups, after adjustment for clinical center and race or ethnic group.
The calcium with vitamin D trial was designed to have 85 percent power to detect an intervention effect of 18 percent for hip fracture, assuming a sample size of 35,000 women and an annual hip-fracture rate in the placebo group of 33.6 per 10,000 persons per year. The power to detect an intervention effect of similar magnitude for total fracture was greater than 99 percent.
Results
Baseline Characteristics
Between 1995 and 2000, 36,282 women were randomly assigned in the calcium with vitamin D trial: 18,176 were assigned to active supplementation, and 18,106 to placebo. Demographic characteristics, health behavior, and medical history were well balanced between the groups at baseline (Table 1Table 1
Characteristics of the Participants in the Calcium with Vitamin D Trial at the Time of the WHI Screening, According to Randomly Assigned Group.). The women had a mean age of 62 years and a mean body-mass index (the weight in kilograms divided by the square of the height in meters) of 29. Sixteen percent were not white. The average calcium intake was approximately 1150 mg per day. More than half the women (52 percent) were taking hormone therapy (10,725 reported personal use of hormones, and 8117 had been randomly assigned to receive active-hormone study medication). The rate of use of other osteoporosis medications was 1 percent (1 used a selective estrogen-receptor modulator, 366 bisphosphonate, and 33 calcitonin).Retention and Adherence
At the termination of the trial, on March 31, 2005, 1551 participants (4.3 percent) had died and 2.7 percent had withdrawn or had been lost to follow-up (Figure 1Figure 1
Profile of the Calcium with Vitamin D Trial of the Women's Health Initiative (WHI).). The rate of adherence (defined as use of 80 percent or more of the assigned study medication) ranged from 60 to 63 percent during the first three years of follow-up, with an additional 13 to 21 percent of the participants taking at least half of their study pills. At the end of the trial, 76 percent were still taking the study medication, and 59 percent were taking 80 percent or more of it.Bone Mineral Density
Women receiving calcium with vitamin D supplements had greater preservation of total-hip bone mineral density at annual visits 3, 6, and 9 than women assigned to placebo (Figure 2Figure 2
Hip, Spine, and Total-Body Bone Mineral Density (BMD).). The mean differences between the treatment groups, all in favor of calcium with vitamin D, were 0.59 percent at annual visit 3, 0.86 percent at annual visit 6, and 1.06 percent at annual visit 9. Nonsignificant differences favoring the calcium with vitamin D group were observed in spine and whole-body bone mineral density.Hip and Other Fractures
During a mean of 7.0 years of follow-up, there were 2102 fractures (including 175 hip fractures) among women assigned to calcium with vitamin D and 2158 fractures (including 199 hip fractures) among women assigned to placebo (Table 2Table 2
Effect of Calcium with Vitamin D Supplementation on Clinical Outcomes, According to Randomly Assigned Group.). Annualized fracture rates per 10,000 person-years in the calcium with vitamin D and placebo groups, respectively, were as follows: hip fracture, 14 and 16; fracture of the lower arm or wrist, 44 and 44; clinical vertebral fracture, 14 and 15; and total fractures, 164 and 170.Women assigned to calcium with vitamin D supplements had a nonsignificant, 12 percent lower risk of hip fracture than women assigned to placebo (hazard ratio, 0.88; 95 percent confidence interval, 0.72 to 1.08). There were no significant reductions in clinical vertebral fracture, fracture of the lower arm or wrist, or total fractures (Table 2).
Secondary and Subgroup Analyses
Among women who were adherent (i.e., those who took at least 80 percent of their study medication), calcium with vitamin D supplementation resulted in a 29 percent reduction in hip fracture (hazard ratio, 0.71; 95 percent confidence interval, 0.52 to 0.97); there were 167 cases of hip fracture among these women (Table 2). The hazard ratio based on the inverse-probability weighting method was nearly identical. For all other fracture outcomes, the hazard ratios were similar to those obtained in the intention-to-treat analyses.
The hazard ratio for hip fracture among women 60 years of age or older was 0.79 (95 percent confidence interval, 0.64 to 0.98), with an indication of increased risk among women 50 to 59 years of age (P for interaction=0.05) (Table 3Table 3
Effect of Calcium with Vitamin D Supplementation on Hip Fractures, According to Baseline Characteristics.). There was a lower hazard ratio among women with no falls than among women with at least one fall (P for interaction=0.05). No other significant interactions were observed for any fracture outcome.There was no evidence that either baseline levels of total calcium or total vitamin D intake modified the association between calcium with vitamin D supplementation and fracture (Table 3). Dietary calcium intake remained stable during follow-up, whereas the intake of calcium from supplements increased by approximately 100 mg daily in both treatment groups. In both treatment groups, participants with initially low levels of total calcium intake (<400 mg daily) had larger increases (200 mg daily) in supplemental calcium intake than did other participants. The effects of calcium with vitamin D intervention on the risk of hip fracture tended to be greater among participants not using personal calcium supplements during follow-up: the hazard ratio was 0.70 (95 percent confidence interval, 0.51 to 0.98) among nonusers, 0.87 (95 percent confidence interval, 0.61 to 1.24) among those taking less than 500 mg per day, and 1.22 (95 percent confidence interval, 0.83 to 1.79) among those taking 500 mg or more per day (P for interaction=0.11).
Use of osteoporosis medications increased during follow-up, with 3890 of the women (10.7 percent) taking alendronate, 654 (1.8 percent) taking risedronate, 1094 (3.0 percent) taking raloxifene, and 451 (1.2 percent) taking calcitonin. Censoring data from these participants after their first recorded use of these medications yielded hazard ratios of 0.87 (95 percent confidence interval, 0.69 to 1.09) for hip fracture and 0.93 (95 percent confidence interval, 0.74 to 1.18) for clinical vertebral fracture.
Serum Vitamin D Levels
In the nested case–control assessment of 25-hydroxyvitamin D, the mean (±SD) baseline 25-hydroxyvitamin D level was 46.0±22.6 nmol per liter among the participants who had hip fracture and 48.4±23.5 nmol per liter among their controls (P=0.17). No statistically significant interactions were found between calcium with vitamin D supplementation and baseline 25-hydroxyvitamin D level with respect to either hip or total fractures (Table 4Table 4
Odds Ratios for Hip Fracture and Total Fractures According to Quartiles of Serum 25-Hydroxyvitamin D Level and Study Group, as Determined in a Nested Case–Control Study.).Interaction between Calcium with Vitamin D and Hormone Therapy
Of the women in the WHI calcium with vitamin D trial, 16,089 were concomitantly enrolled in the WHI Hormone Therapy trial, in which estrogen was found to have strong effects on hip and other fractures.31,32 The hazard ratios for hip fracture with calcium with vitamin D supplementation were 0.58 (95 percent confidence interval, 0.37 to 0.93) among women assigned to active hormone therapy and 1.15 (95 percent confidence interval, 0.81 to 1.63) among those assigned to placebo (P for interaction=0.07). When the analyses included both exposure in the randomized Hormone Therapy trial and personal use, the trend toward an interaction between calcium with vitamin D supplementation and hormone therapy with respect to hip fracture was no longer present.
Safety and Tolerability
As of March 31, 2005, there were 744 deaths in the calcium with vitamin D group and 807 deaths in the placebo group (hazard ratio, 0.91; 95 percent confidence interval, 0.83 to 1.01). No statistically significant risks or benefits were seen with regard to any major disease outcomes, including cardiovascular diseases and cancer. Kidney stones were reported by 449 women in the calcium with vitamin D group, as compared with 381 women in the placebo group (hazard ratio, 1.17; 95 percent confidence interval, 1.02 to 1.34), and appeared to be unrelated to high baseline calcium intake. There were no significant differences in gastrointestinal symptoms: 8.9 percent of the participants in the placebo group and 10.3 percent of those in the calcium with vitamin D group reported moderate-to-severe constipation, and 19.5 percent and 20.4 percent, respectively, reported bloating or gas.
Discussion
The WHI calcium with vitamin D study was a large-scale, randomized, double-blind, placebo-controlled trial designed to test whether calcium and vitamin D supplementation reduced the risk of hip fracture in a large population of healthy postmenopausal women. The trial demonstrated that calcium with vitamin D supplementation diminishes bone loss at the hip, but the observed 12 percent reduction in the incidence of hip fracture (the primary outcome) was not statistically significant. There were no significant reductions in the incidence of clinical vertebral fractures, fractures of the lower arm or wrist, or total fractures. The main adverse effect noted was a small but significant increase in the proportion of women with renal calculi.
There are several plausible alternative explanations for the results seen in the intention-to-treat analyses. It is conceivable that calcium with vitamin D, at the doses studied in the WHI, has no significant effect on fracture reduction. The observed lack of efficacy in reducing clinical vertebral fractures is discordant with the results of meta-analyses of clinical trials that suggest a trend toward a small reduction in vertebral fractures with calcium alone6 and a significant, 37 percent reduction in vertebral fractures with vitamin D supplementation.22 The lack of a reduction in the risk of hip or total fractures would be consistent with the findings of recent studies that showed no evidence of reduction in nonvertebral fractures in healthy, older women living in the community.15,18,19
The effect of calcium with vitamin D supplementation on fracture reduction might require higher doses of vitamin D than were used in the WHI. This dose–response concept33 is supported by studies indicating that supplementation with 400 IU of vitamin D has a small effect or no effect on the risk of fracture,16,17 whereas the majority of studies supporting a benefit from calcium with vitamin D supplements evaluated vitamin D at doses that were the equivalent of 600 IU or higher.8,10,13,14,33
It is also plausible that there was a benefit only among the women who adhered to the study treatment. Although 76 percent of the women in this trial were still taking study pills at the end of the trial, only 59 percent were taking the intended dose. In sensitivity analyses, there was a decrease in the risk of hip fracture among adherent participants, yielding an absolute benefit of four fewer hip fractures per 10,000 women, or a significant, 29 percent relative decrease — a finding consistent with the results of other trials that showed that efficacy in fracture reduction is enhanced among women adherent to calcium with vitamin D supplementation11 or is present only in this group.
This trial cannot separate the independent effects of calcium and vitamin D. The study population was not selected to be deficient in calcium and vitamin D, since the participants were allowed to take multivitamins as well as calcium and vitamin D up to specified levels during the trial. The average daily total calcium intake at randomization was estimated to be 1100 to 1200 mg; only 7.2 percent of the participants had an intake of less than 400 mg.
The effect of calcium with vitamin D supplements may also differ according to baseline vitamin D levels. Chapuy et al. reported that calcium with vitamin D (1000 mg of calcium and 800 IU of vitamin D per day) significantly reduced the risk of hip and nonvertebral fractures among elderly women who were believed to be vitamin D–deficient (on the basis of low vitamin D levels in a subgroup analysis at baseline).10 Studies involving persons who were potentially less deficient in vitamin D have failed to confirm this benefit.18 We found no significant interactions between baseline serum 25-hydroxyvitamin D levels and a calcium with vitamin D treatment effect.
Finally, it is also plausible that calcium with vitamin D supplementation has a real but small effect in reducing the risk of hip fracture among postmenopausal women, but the WHI calcium with vitamin D trial was not sufficiently powered to detect such a small effect, even with 36,282 women enrolled. The trial design assumed an 18 percent reduction in the risk of hip fracture and projected a hip-fracture rate (approximately 34 per 10,000 persons per year) that was more than twice that observed (16 per 10,000). The lower-than-projected hip-fracture rate reduced the power of the study to approximately 48 percent. This may be attributable to the higher-than-anticipated body-mass index, the recruitment of fewer women over the age of 70 years than was projected, or a fracture rate already suppressed by high personal calcium intake or hormone-therapy use. Some support is provided by subgroup analyses suggesting that among women over the age of 60 years who had a higher absolute risk of hip fracture, calcium with vitamin D supplementation significantly reduced the risk of hip fractures.
The trend toward a reduction in the incidence of hip fracture, with no benefit at other skeletal sites, could be consistent with the pathophysiology of hip fracture relative to other osteoporotic fractures. Up to 60 percent of patients with hip fractures have one or more biomarkers consistent with a negative calcium balance, such as secondary hyperparathyroidism, low 25-hydroxyvitamin D levels, or low urine calcium excretion.34 These perturbations in calcium metabolism associated with hip fracture might be amenable to treatments that would improve the calcium balance.
The trial yielded conflicting data regarding hip fracture and the interaction between hormone use and calcium with vitamin D supplementation. Though not statistically significant, the observed interaction between active calcium with vitamin D and hormone therapy may reflect a synergistic role of enhanced calcium balance with hormone therapy. This possibility is consistent with the previously reported additive effects of calcium with vitamin D and hormone therapy on bone mineral density.35,36 However, when hormone-therapy use outside the trial was included, there was no interaction, and a 17 percent reduction in the incidence of hip fracture with calcium with vitamin D was observed among participants who had never used hormone therapy (hazard ratio, 0.83; 95 percent confidence interval, 0.61 to 1.14).
Participants in the WHI trial were healthy, postmenopausal women living in the community who were generally free of disability. The average calcium intake at baseline exceeded 1000 mg per day, close to the current national recommendations.37 Nevertheless, we found significantly higher hip bone density but a nonsignificant reduction (12 percent) in the rate of hip fracture among those assigned to calcium with vitamin D. In secondary analyses, the intervention effect appeared greater among women who adhered to the regimen, women over 60 years of age, and women not taking personal calcium supplements. Using the intention-to-treat results from this study, we estimate that for healthy postmenopausal women over the age of 50 years, the number needed to treat to prevent one hip fracture per year is 5045. This number would be reduced to 1914 among women over the age of 60 years, who are at higher absolute risk for hip fracture. Although the statistically null primary effect argues against recommending universal calcium with vitamin D supplementation for already calcium-replete women, the findings provide evidence of a positive effect of calcium with vitamin D on bone health in older postmenopausal women.
Supported by the National Heart, Lung, and Blood Institute and the General Clinical Research Center program of the National Center for Research Resources, Department of Health and Human Services. The active study drug and placebo were supplied by GlaxoSmithKline Consumer Healthcare (Pittsburgh).
Dr. Jackson reports having received consulting fees from Procter & Gamble Pharmaceuticals and lecture fees from the Alliance for Better Bone Health; she also reports that she currently receives grant support from Novartis. Dr. LaCroix reports having received consulting fees from Pfizer, Procter & Gamble, and the Alliance for Better Bone Health and having received a lecture fee from Schering-Plough. Dr. Robbins reports that he has worked on grants with industry support but that he has received no salary support. Dr. Lewis reports that she currently has grant support from Pfizer and Novartis. Dr. Brunner reports that he is principal investigator for a study funded by the National Cancer Institute of Canada and Pfizer through March 31, 2007. Dr. Cauley reports having received consulting fees from Novartis for serving on the HORIZON Study steering committee and grant support from Lilly, Pfizer, and Novartis. Dr. Hays reports having received lecture fees for conferences sponsored by Procter & Gamble Pharmaceuticals. Dr. Howard reports having received lecture fees from Schering-Plough and having served as a consultant for Merck, the Egg Nutrition Council, and General Mills. Dr O'Sullivan reports that she currently receives grant support from Pfizer. Dr. Assaf reports having been an employee of Pfizer since December 2002 and owning Pfizer stock and stock options. No other potential conflict of interest relevant to this article was reported.
We are indebted to the investigators and staff at the WHI Clinical Centers, the WHI Clinical Coordinating Center, and the National Heart, Lung, and Blood Institute program office for their dedicated efforts; to Joseph Larson for his invaluable expertise in completing the statistical analysis reported in this article; and most important, to the WHI participants for their extraordinary commitment to the WHI calcium with vitamin D study.
Source Information
Address reprint requests to Dr. Jackson at the Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr., Columbus, OH 43210, or at jackson.20@osu.edu.
The Women's Health Initiative investigators are listed in Appendix 1. The authors' affiliations are listed in Appendix 2.
Appendix
Appendix 1
The WHI investigators are as follows: Program Office (National Heart, Lung, and Blood Institute, Bethesda, Md.): B. Alving, J. Rossouw, L. Pottern, S. Ludlam, J. McGowan, N. Geller, and L. Ford. Clinical Coordinating Centers: Fred Hutchinson Cancer Research Center, Seattle — R. Prentice, G. Anderson, A. LaCroix, R. Patterson, A. McTiernan, B. Cochrane, J. Hunt, L. Tinker, C. Kooperberg, M. McIntosh, C.Y. Wang, C. Chen, D. Bowen, A. Kristal, J. Stanford, N. Urban, N. Weiss, and E. White; Wake Forest University School of Medicine, Winston-Salem, N.C. — S. Shumaker, R. Prineas, and M. Naughton; Medical Research Laboratories, Highland Heights, Ky. — E. Stein, P. Laskarzewski; San Francisco Coordinating Center, San Francisco — S.R. Cummings, M. Nevitt, and L. Palermo; University of Minnesota, Minneapolis — L. Harnack; Fisher BioServices, Rockville, Md. — F. Cammarata and S. Lindenfelser; University of Washington, Seattle — B. Psaty and S. Heckbert. Clinical Centers: Albert Einstein College of Medicine, Bronx, N.Y. — S. Wassertheil-Smoller, W. Frishman, J. Wylie-Rosett, D. Barad, and R. Freeman; Baylor College of Medicine, Houston — J. Hays, R. Young, J. Anderson, S. Lithgow, and P. Bray; Brigham and Women's Hospital, Harvard Medical School, Boston — J.E. Manson, J.M. Gaziano, C. Chae, K. Rexrode, and C. Solomon; Brown University, Providence, R.I. — A.R. Assaf, C. Wheeler, C. Eaton, and M. Cyr; Emory University, Atlanta — L. Phillips, M. Pedersen, O. Strickland, M. Huber, and V. Porter; Fred Hutchinson Cancer Research Center, Seattle — S.A.A. Beresford, V.M. Taylor, N.F. Woods, M. Henderson, and R. Andersen; George Washington University, Washington, D.C. — J. Hsia, N. Gaba, and J. Ascensao; Harbor–UCLA Research and Education Institute, Torrance, Calif. — R. Chlebowski, R. Detrano, A. Nelson, and M. Geller; Kaiser Permanente Center for Health Research, Portland, Oreg. — E. Whitlock, P. Elmer, V. Stevens, and N. Karanja; Kaiser Permanente Division of Research, Oakland, Calif. — B. Caan, S. Sidney, G. Bailey, and J. Hirata; Medical College of Wisconsin, Milwaukee — J.M. Kotchen, V. Barnabei, T.A. Kotchen, M.C. Gilligan, and J. Neuner; MedStar Research Institute and Howard University, Washington, D.C. — B.V. Howard, L. Adams-Campbell, L. Lessin, M. Rainford, and G. Uwaifo; Northwestern University, Chicago and Evanston, Ill. — L. Van Horn, P. Greenland, J. Khandekar, K. Liu, and C. Rosenberg; Rush University Medical Center, Chicago — H. Black, L. Powell, E. Mason, and M. Gulati; Stanford Prevention Research Center, Stanford, Calif. — M.L. Stefanick, M.A. Hlatky, B. Chen, R.S. Stafford, and S. Mackey; State University of New York at Stony Brook, Stony Brook — D. Lane, I. Granek, W. Lawson, G. San Roman, and C. Messina; Ohio State University, Columbus — R. Jackson, R. Harris, E. Paskett, W.J. Mysiw, and M. Blumenfeld; University of Alabama at Birmingham, Birmingham — C.E. Lewis, A. Oberman, J.M. Shikany, M. Safford, and M. Fouad; University of Arizona, Tucson and Phoenix — T. Bassford, C. Thomson, M. Ko, A.M. Lopez, and C. Ritenbaugh; University at Buffalo, Buffalo, N.Y. — J. Wactawski-Wende, M. Trevisan, E. Smit, S. Graham, and J. Chang; University of California at Davis, Sacramento — J. Robbins and S. Yasmeen; University of California at Irvine, Irvine — F.A. Hubbell, G. Frank, N. Wong, N. Greep, and B. Monk; University of California at Los Angeles, Los Angeles — H. Judd, D. Heber, and R. Elashoff; University of California at San Diego, La Jolla and Chula Vista — R.D. Langer, M.H. Criqui, G.T. Talavera, C.F. Garland, and M.A. Allison; University of Cincinnati, Cincinnati — M. Gass and S. Wernke; University of Florida, Gainesville and Jacksonville — M. Limacher, M. Perri, A. Kaunitz, R.S. Williams, and Y. Brinson; University of Hawaii, Honolulu — J.D. Curb, H. Petrovitch, B. Rodriguez, K. Masaki, and S. Sharma; University of Iowa, Iowa City and Davenport — R. Wallace, J. Torner, S. Johnson, L. Snetselaar, and J. Robinson; University of Massachusetts, Fallon Clinic, Worcester — J. Ockene, M. Rosal, I. Ockene, R. Yood, and P. Aronson; University of Medicine and Dentistry of New Jersey, Newark — N. Lasser, B. Singh, V. Lasser, J. Kostis, and P. McGovern; University of Miami, Miami — M.J. O'Sullivan, L. Parker, T. DeSantis, D. Fernandez, and P. Caralis; University of Minnesota, Minneapolis — K.L. Margolis, R.H. Grimm, M.F. Perron, C. Bjerk, and S. Kempainen; University of Nevada, Reno — R. Brunner, W. Graettinger, V. Oujevolk, and M. Bloch; University of North Carolina, Chapel Hill — G. Heiss, P. Haines, D. Ontjes, C. Sueta, and E. Wells; University of Pittsburgh, Pittsburgh — L. Kuller, J. Cauley, and N.C. Milas; University of Tennessee Health Science Center, Memphis — K.C. Johnson, S. Satterfield, R.W. Ke, S. Connelly, and F. Tylavsky; University of Texas Health Science Center, San Antonio — R. Brzyski, R. Schenken, J. Trabal, M. Rodriguez-Sifuentes, and C. Mouton; University of Wisconsin, Madison — G.E. Sarto, D. Laube, P. McBride, J. Mares-Perlman, and B. Loevinger; Wake Forest University School of Medicine, Winston-Salem, N.C. — D. Bonds, G. Burke, R. Crouse, M. Vitolins, and S. Washburn; Wayne State University School of Medicine and Hutzel Hospital, Detroit — S. Hendrix, M. Simon, and G. McNeeley. Former Principal Investigators and Project Officers: Baylor College of Medicine — J. Foreyt; Emory University — D. Hall, S. McNagny, and N. Watts; George Washington University — Valery Miller; Kaiser, Oakland — R. Hiatt; Kaiser, Portland — B. Valanis; National Cancer Institute — C. Clifford (deceased); University of Arizona — T. Moon; University of California, Irvine — F. Meyskens, Jr.; University of Cincinnati — J. Liu; University of Miami — Marianna Baum; University of Nevada — S. Daugherty (deceased); University of North Carolina, Chapel Hill — D. Sheps, B. Hulka; University of Tennessee, Memphis — W. Applegate; University of Wisconsin — C. Allen (deceased). Data and Safety Monitoring Board: J. Wittes (chair), E. Braunwald, M. Chesney, H. Cohen, E. Barrett-Connor, D. DeMets, L. Dunn, J. Dwyer, R.P. Heaney, D. Marson, V. Vogel, L. Walters, K. Yaffe, and S. Yusuf.
Appendix 2
From the Ohio State University, Columbus (R.D.J.); the Fred Hutchinson Cancer Research Center, Seattle (A.Z.L., R.L.P., G.L.A.); the University of Cincinnati, Cincinnati (M.G.); the University of Iowa, Iowa City and Davenport (R.B.W.); the University of California at Davis, Sacramento (J.R.); the University of Alabama at Birmingham, Birmingham (C.E.L.); the University of Arizona, Tucson and Phoenix (T.B.); the University of Washington, Seattle (S.A.A.B.); Rush Medical Center, Chicago (H.R.B.); the University of Hawaii, Honolulu (P.B.); Wake Forest University School of Medicine, Winston-Salem, N.C. (D.E.B.); the University of Nevada, Reno (R.L.B.); the University of Texas Health Science Center, San Antonio (R.G.B.); Kaiser Permanente Division of Research, Oakland, Calif. (B.C.); the University of Pittsburgh, Pittsburgh (J.A.C., L.H.K.); the Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, Calif. (R.T.C.); San Francisco Coordinating Center, San Francisco (S.R.C.); State University of New York at Stony Brook, Stony Brook (I.G.); Baylor College of Medicine, Houston (J.H.); the University of North Carolina, Chapel Hill (G.H.); Wayne State University School of Medicine and Hutzel Hospital, Detroit (S.L.H.); MedStar Research Institute and Howard University, Washington, D.C. (B.V.H.); George Washington University Medical Center, Washington, D.C. (J.H.); the University of California at Irvine, Irvine (F.A.H.); the University of Tennessee Health Science Center, Memphis (K.C.J.); the University of California at Los Angeles, Los Angeles (H.J.); Medical College of Wisconsin, Milwaukee (J.M.K.); the University of California at San Diego, La Jolla and Chula Vista (R.D.L.); the University of Medicine and Dentistry of New Jersey, Newark (N.L.L.); the University of Florida, Gainesville and Jacksonville (M.C.L.); the National Lung, Heart, and Blood Institute, Bethesda, Md. (S.L.); Brigham and Women's Hospital and Harvard Medical School, Boston (J.E.M.); the University of Minnesota, Minneapolis (K.L.M.); the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Md. (J.M.); the University of Massachusetts, Fallon Clinic, Worcester (J.K.O.); the University of Miami, Miami (M.J.O.); Emory University, Atlanta (L.P.); the University of Wisconsin, Madison (G.E.S.); Stanford Prevention Research Center, Stanford, Calif. (M.L.S.); Northwestern University, Chicago and Evanston, Ill. (L.V.H.); the University of Buffalo, Buffalo, N.Y. (J.W.-W.); Kaiser Permanente Center for Health Research, Portland, Oreg. (E.W.); Brown University, Providence, R.I. (A.R.A.); and the Albert Einstein College of Medicine, Bronx, N.Y. (D.B.).
- References
References
1
Looker AC ,Orwoll ES ,Johnston CC Jr , et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-1768
CrossRef | Web of Science | Medline2
Melton LJ III . How many women have osteoporosis now? J Bone Miner Res 1995;10:175-177
CrossRef | Web of Science | Medline3
Healthcare Cost and Utilization Project. HCUP Nationwide Inpatient Sample (NIS), 2003. (Accessed January 26, 2006, at http://www.hcup-us.ahrq.gov/nisoverview.jsp.)
4
Chevalley T ,Rizzoli R ,Nydegger V , et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 1994;4:245-252
CrossRef | Web of Science | Medline5
Cumming RG . Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990;47:194-201
CrossRef | Web of Science | Medline6
Shea B ,Wells G ,Cranney A , et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-559
CrossRef | Web of Science | Medline7
Bischoff-Ferrari HA ,Dawson-Hughes B ,Willett WC , et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006
CrossRef | Web of Science | Medline8
Bischoff-Ferrari HA ,Willett WC ,Wong JB ,Giovannucci E ,Dietrich T ,Dawson-Hughes B . Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264
CrossRef | Web of Science | Medline9
Dawson-Hughes B ,Harris SS ,Krall EA ,Dallal GE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676
Full Text | Web of Science | Medline10
Chapuy MC ,Arlot ME ,Duboeuf F ,Meunier PJ . Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-1642
Full Text | Web of Science | Medline11
Chapuy MC ,Arlot ME ,Delmas PD ,Meunier PJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-1082
CrossRef | Web of Science | Medline12
Recker RR ,Hinders S ,Davies KM , et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996;11:1961-1966
CrossRef | Web of Science | Medline13
Trivedi DP ,Doll R ,Khaw KT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469-472
CrossRef | Web of Science | Medline14
Chapuy MC ,Pamphile P ,Paris E , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257-264
CrossRef | Web of Science | Medline15
Larsen ER ,Mosekilde L ,Foldspang A . Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004;19:370-378
CrossRef | Web of Science | Medline16
Meyer HE ,Smedshaug GB ,Kvaavik E ,Falch JA ,Tverdal A ,Pedersen JI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002;17:709-715
CrossRef | Web of Science | Medline17
Lips P ,Graafmans WC ,Ooms ME ,Bezemer PD ,Bouter LM . Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124:400-406
Web of Science | Medline18
Grant AM ,Avenell A ,Campbell MK , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-1628
CrossRef | Web of Science | Medline19
Porthouse J ,Cockayne S ,King C , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330:1003-1003
CrossRef | Web of Science | Medline20
Cumming RG ,Nevitt MC . Calcium for the prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997;12:1321-1329
CrossRef | Web of Science | Medline21
Kanis JA . The use of calcium in the management of osteoporosis. Bone 1999;24:279-290
CrossRef | Web of Science | Medline22
Papadimitropoulos E ,Wells G ,Shea B , et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII. Meta-analyses of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-569
CrossRef | Web of Science | Medline23
Gillespie WJ ,Avenell A ,Henry DA ,O'Connell DL ,Robertson J . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2001;1:CD000227-CD000227
Medline24
Jackson RD ,LaCroix AZ ,Cauley JA ,McGowan J . The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:Suppl:S98-S106
CrossRef | Web of Science | Medline25
Wactawski-Wende J ,Kotchen JM ,Anderson GL , et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696
Full Text | Web of Science | Medline26
Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, D.C.: National Academy Press, 1997:38-144.
27
Yates AA ,Schlicker SA ,Suitor CW . Dietary Reference Intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706
CrossRef | Web of Science | Medline28
Patterson RE ,Kristal AR ,Tinker LF ,Carter RA ,Bolton MP ,Agurs-Collins T . Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178-187
CrossRef | Web of Science | Medline29
Robins JM ,Finkelstein DM . Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779-781
CrossRef | Web of Science | Medline30
Garland CF ,Garland FC . Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227-231
CrossRef | Web of Science | Medline31
Cauley JA ,Robbins J ,Chen Z , et al. Effects of estrogen plus progestin on the risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738
CrossRef | Web of Science | Medline32
Anderson GL ,Limacher M ,Assaf AR , et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
CrossRef | Web of Science | Medline33
Vieth R . Why the optimal requirement for vitamin D3 is probably higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004;89:575-579
CrossRef | Web of Science | Medline34
LeBoff MS ,Kohlmeier L ,Hurwitz S ,Franklin J ,Wright J ,Glowacki J . Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505-1511
CrossRef | Web of Science | Medline35
Ettinger B ,Genant HK ,Cann CE . Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987;106:40-45
Web of Science | Medline36
Sirola J ,Kroger H ,Sandini L , et al. Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study. Calcif Tissue Int 2003;72:659-665
CrossRef | Web of Science | Medline37
Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, Md.: Office of the Surgeon General, 2004.
- Citing Articles (384)
Citing Articles
1
J.-J. Body, P. Bergmann, S. Boonen, J.-P. Devogelaer, E. Gielen, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis International 23:S1, 1-23
CrossRef2
Martine F. Luxwolda, Remko S. Kuipers, Ido P. Kema, D. A. Janneke Dijck-Brouwer, Frits A. J. Muskiet. (2012) Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. British Journal of Nutrition1-5
CrossRef3
E. Michael Lewiecki, John P. Bilezikian, Lawrence G. Jankowski, Eugene V. McCloskey, Paul D. Miller, Sarah L. Morgan, Eric S. Orwoll, John T. Potts. (2012) Proceedings of the 2011 Santa Fe Bone Symposium. Journal of Clinical Densitometry 15:1, 1-20
CrossRef4
Peter Greaves. 2012. Musculoskeletal System. , 157-206.
CrossRef5
Staffan Lindeberg. (2012) Paleolithic diets as a model for prevention and treatment of western disease. American Journal of Human Biologyn/a-n/a
CrossRef6
Marius Racovan, Brian Walitt, Christopher E. Collins, Mary Pettinger, Christine G. Parks, James M. Shikany, Jean Wactawski-Wende, JoAnn E. Manson, Larry Moreland, Nicole Wright, Rebecca Jackson, Barbara V. Howard. (2011) Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women’s Health Initiative Calcium plus Vitamin D trial. Rheumatology International
CrossRef7
Itsuo Gorai, Shin Hattori, Yaku Tanaka, Yasuhisa Iwaoki. (2011) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. Journal of Bone and Mineral Metabolism
CrossRef8
M. J. Bolland, A. Grey, I. R. Reid. (2011) Re: The calcium scare: what would Austin Bradford Hill have thought?. Osteoporosis International 22:12, 3079-3080
CrossRef9
Francisco J.A. de Paula, Clifford J. Rosen. (2011) Vitamin D Safety and Requirements. Archives of Biochemistry and Biophysics
CrossRef10
Khashayar Sakhaee, Charles Pak. (2011) Superior calcium bioavailability of effervescent potassium calcium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases
CrossRef11
K. L. Margolis, L. W. Martin, R. M. Ray, T. J. Kerby, M. A. Allison, J. D. Curb, T. A. Kotchen, S. Liu, S. Wassertheil-Smoller, J. E. Manson, . (2011) A Prospective Study of Serum 25-Hydroxyvitamin D Levels, Blood Pressure, and Incident Hypertension in Postmenopausal Women. American Journal of Epidemiology
CrossRef12
Eleni Linos, Elizabeth Keiser, Matthew Kanzler, Kristin L. Sainani, Wayne Lee, Eric Vittinghoff, Mary-Margaret Chren, Jean Y. Tang. (2011) Sun protective behaviors and vitamin D levels in the US population: NHANES 2003–2006. Cancer Causes & Control
CrossRef13
Marie-Paule Lecart, Jean-Yves Reginster. (2011) Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 12:16, 2533-2552
CrossRef14
Kavitha K. Reddy, Barbara A. Gilchrest. (2011) Iatrogenic effects of photoprotection recommendations on skin cancer development, vitamin D levels, and general health. Clinics in Dermatology 29:6, 644-651
CrossRef15
Dean Assimos. (2011) Re: Urinary Tract Stone Occurrence in the Women's Health Initiative (WHI) Randomized Clinical Trial of Calcium and Vitamin D Supplements. The Journal of Urology 186:5, 1918
CrossRef16
Robert Skully, Aroob Shanaah Saleh. (2011) Aging and the Effects of Vitamins and Supplements. Clinics in Geriatric Medicine 27:4, 591-607
CrossRef17
A. Caroli, A. Poli, D. Ricotta, G. Banfi, D. Cocchi. (2011) Invited review: Dairy intake and bone health: A viewpoint from the state of the art. Journal of Dairy Science 94:11, 5249-5262
CrossRef18
Lluís Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria, Estíbaliz Loza. (2011) Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatología Clínica 7:6, 357-379
CrossRef19
Lluis Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i. Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria, Estíbaliz Loza. (2011) 2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis. Reumatolog ía Cl ínica (English Edition)
CrossRef20
Woo Young Jang, Moon Sang Chung, Goo Hyun Baek, Cheol Ho Song, Hoyune Esther Cho, Hyun Sik Gong. (2011) Vitamin D levels in post-menopausal Korean women with a distal radius fracture. Injury
CrossRef21
Cristina Carbonell, Adolfo Díez, Joaquín Calaf, María Teresa Caloto, Gonzalo Nocea, Nuria Lara. (2011) Pauta de tratamiento inicial en pacientes con osteoporosis: uso de antirresortivos y suplementos farmacológicos (calcio y vitamina D) en la práctica clínica. Reumatología Clínica
CrossRef22
Heike A. Bischoff-Ferrari. (2011) Relevance of vitamin D in muscle health. Reviews in Endocrine and Metabolic Disorders
CrossRef23
Judith M. E. Walsh, Megan McNamara, Redonda G. Miller, Eleanor Bimla Schwarz. (2011) Update in Women’s Health for the General Internist. Journal of General Internal Medicine
CrossRef24
John Anderson, Sanford Garner. 2011. Calcium and Bone. .
CrossRef25
Felicia Cosman, Jeri Nieves. 2011. Skeletal Racial Differences. .
CrossRef26
Paul Lee. (2011) Vitamin D metabolism and deficiency in critical illness. Best Practice & Research Clinical Endocrinology & Metabolism 25:5, 769-781
CrossRef27
Dima A Youssef, Adel M El Abbassi, Della C Cutchins, Shalini Chhabra, Alan N Peiris. (2011) Vitamin D deficiency: Implications for acute care in the elderly and in patients with chronic illness. Geriatrics & Gerontology International 11:4, 395-407
CrossRef28
Robin Taylor Wilson, Alanna N. Roff, P. Jenny Dai, Tracey Fortugno, Jonathan Douds, Gang Chen, Gary L. Grove, Sheila Ongeri Nikiforova, Jill Barnholtz-Sloan, Tony Frudakis, Vernon M. Chinchilli, Terryl J. Hartman, Laurence M. Demers, Mark D. Shriver, Victor A. Canfield, Keith C. Cheng. (2011) Genetic ancestry, skin reflectance and pigmentation genotypes in association with serum vitamin D metabolite balance. Hormone Molecular Biology and Clinical Investigation 7:1, 279-293
CrossRef29
K. Graf. (2011) Erhöht die Substitution von Kalzium und Vitamin D das Herzinfarktrisiko?. Der Kardiologe 5:5, 376-378
CrossRef30
Mohamed A. Elkoushy, Ramsey Sabbagh, Bernard Unikowsky, Sero Andonian. (2011) Prevalence and Metabolic Abnormalities of Vitamin D–Inadequate Patients Presenting with Urolithiasis to a Tertiary Stone Clinic. Urology
CrossRef31
JoAnn E. Manson, Shari S. Bassuk, I-Min Lee, Nancy R. Cook, Michelle A. Albert, David Gordon, Elaine Zaharris, Jean G. MacFadyen, Eleanor Danielson, Jennifer Lin, Shumin M. Zhang, Julie E. Buring. (2011) The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials
CrossRef32
Omar Khokhar, Timothy Lipman. 2011. Micronutrients. , 265-282.
CrossRef33
G. Grimnes, R. Joakimsen, Y. Figenschau, P. A. Torjesen, B. Almås, R. Jorde. (2011) The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial. Osteoporosis International
CrossRef34
Joan C. Lo, Sherri-Ann M. Burnett-Bowie, Joel S. Finkelstein. (2011) Bone and the Perimenopause. Obstetrics and Gynecology Clinics of North America 38:3, 503-517
CrossRef35
Jesús Alberto García Vadillo. (2011) Suplementos de calcio y vitamina D ¿para todos?: Pros. Reumatología Clínica 7, 34-39
CrossRef36
W B Grant. (2011) An estimate of the global reduction in mortality rates through doubling vitamin D levels. European Journal of Clinical Nutrition 65:9, 1016-1026
CrossRef37
Stefania Russo, Luciano Carlucci, Cristiana Cipriani, Alessandro Ragno, Sara Piemonte, Romano Del Fiacco, Jessica Pepe, Valeria Fassino, Serena Arima, Elisabetta Romagnoli, Salvatore Minisola. (2011) Metabolic Changes Following 500 μg Monthly Administration of Calcidiol: A Study in Normal Females. Calcified Tissue International 89:3, 252-257
CrossRef38
Estíbaliz Loza Santamaría. (2011) Suplementos de calcio y vitamina D ¿para todos?: Contras. Reumatología Clínica 7, 40-45
CrossRef39
Robert L. Brunner, Jean Wactawski-Wende, Bette J. Caan, Barbara B. Cochrane, Rowan T. Chlebowski, Margery L. S. Gass, Elizabeth T. Jacobs, Andrea Z. LaCroix, Dorothy Lane, Joseph Larson, Karen L. Margolis, Amy E. Millen, Gloria E. Sarto, Mara Z. Vitolins, Robert B. Wallace. (2011) The Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial. Nutrition and Cancer 63:6, 827-841
CrossRef40
Roger H Jay, Sarah L Marrinan. (2011) Osteoporosis treatment and the older patient. Reviews in Clinical Gerontology 21:03, 233-245
CrossRef41
Paul Lips, Natasja M. van Schoor. (2011) The effect of vitamin D on bone and osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 25:4, 585-591
CrossRef42
Karen Roush. (2011) Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review. AJN, American Journal of Nursing 111:8, 26-35
CrossRef43
T. Dinizulu, D. Griffin, J. Carey, E. Mulkerrin. (2011) Vitamin D supplementation versus combined calcium and vitamin D in older female patients — An observational study. The journal of nutrition, health & aging 15:8, 605-608
CrossRef44
Goran Bjelakovic, Lise Lotte Gluud, Dimitrinka Nikolova, Kate Whitfield, Jørn Wetterslev, Rosa G Simonetti, Marija Bjelakovic, Christian Gluud, Goran Bjelakovic. 2011. Vitamin D supplementation for prevention of mortality in adults. .
CrossRef45
Camille E Powe, Catherine Ricciardi, Anders H Berg, Delger Erdenesanaa, Gina Collerone, Elizabeth Ankers, Julia Wenger, S Ananth Karumanchi, Ravi Thadhani, Ishir Bhan. (2011) Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. Journal of Bone and Mineral Research 26:7, 1609-1616
CrossRef46
Cayetana Moyano Peregrín, Francisca López Rodríguez, Maria del Mar Castilla Castellano. (2011) Vitamina D e hipertensión arterial. Medicina Clínica
CrossRef47
D. W. Sturdee, A. Pines. (2011) Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14:3, 302-320
CrossRef48
, Stuart H. Ralston, Neil Binkley, Steven Boonen, Douglas P. Kiel, Jean-Yves Reginster, Christian Roux, Liang Chen, Elizabeth Rosenberg, Arthur Santora. (2011) Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency. Calcified Tissue International 88:6, 485-494
CrossRef49
Anna L Zisman, Fredric L Coe, Elaine M Worcester. (2011) Evaluation and management of nephrolithiasis in the aging population with chronic kidney disease. Aging Health 7:3, 423-433
CrossRef50
Caterina Borgna-Pignatti, Maria Rita Gamberini. (2011) Complications of thalassemia major and their treatment. Expert Review of Hematology 4:3, 353-366
CrossRef51
Ada Hung, Maryam Hamidi, Ekaterina Riazantseva, Lilian Thompson, Lianne Tile, George Tomlinson, Brooke Stewart, Angela M. Cheung. (2011) Validation of a calcium assessment tool in postmenopausal Canadian women. Maturitas 69:2, 168-172
CrossRef52
Bhavik M. Bhandari, Hasan Bayat, Kenneth D. Rothstein. (2011) Primary Biliary Cirrhosis. Gastroenterology Clinics of North America 40:2, 373-386
CrossRef53
(2011) Managing osteoporosis in primary care: Highlights from Osteoporosis Canada guidelines. Canadian Pharmacists Journal 144:sp1, S5-S9.e1
CrossRef54
Rui Wang, James H. Ware. (2011) Detecting Moderator Effects Using Subgroup Analyses. Prevention Science
CrossRef55
Kelsey M. Mangano, Stephen J. Walsh, Karl L. Insogna, Anne M. Kenny, Jane E. Kerstetter. (2011) Calcium Intake in the United States from Dietary and Supplemental Sources across Adult Age Groups: New Estimates from the National Health and Nutrition Examination Survey 2003-2006. Journal of the American Dietetic Association 111:5, 687-695
CrossRef56
K. M. Sanders, A. L. Stuart, E. J. Williamson, F. N. Jacka, S. Dodd, G. Nicholson, M. Berk. (2011) Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. The British Journal of Psychiatry 198:5, 357-364
CrossRef57
Joseph J. Lamb, Michael F. Holick, Robert H. Lerman, Veera R. Konda, Deanna M. Minich, Anuradha Desai, Tai C. Chen, Melissa Austin, Jacob Kornberg, Jyh-Lurn Chang, Alex Hsi, Jeffrey S. Bland, Matthew L. Tripp. (2011) Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D3, and vitamin K1 produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome. Nutrition Research 31:5, 347-355
CrossRef58
Dean Assimos. (2011) Urolithiasis/Endourology. The Journal of Urology 185:5, 1747-1750
CrossRef59
Dean Assimos. (2011) Re: Postmenopausal Hormone Use and the Risk of Nephrolithiasis: Results From the Women's Health Initiative Hormone Therapy Trials. The Journal of Urology 185:5, 1749-1750
CrossRef60
Ensrud, Kristine E., Schousboe, John T., . (2011) Vertebral Fractures. New England Journal of Medicine 364:17, 1634-1642
Full Text61
Linda Brewer, David Williams, Alan Moore. (2011) Current and future treatment options in osteoporosis. European Journal of Clinical Pharmacology 67:4, 321-331
CrossRef62
P. N. Sambrook, I. D. Cameron, J. S. Chen, R. G. Cumming, S. Durvasula, M. Herrmann, C. Kok, S. R. Lord, M. Macara, L. M. March, R. S. Mason, M. J. Seibel, N. Wilson, J. M. Simpson. (2011) Does increased sunlight exposure work as a strategy to improve vitamin D status in the elderly: a cluster randomised controlled trial. Osteoporosis International
CrossRef63
Pooneh Salari Sharif, Mohammad Abdollahi, Bagher Larijani. (2011) Current, new and future treatments of osteoporosis. Rheumatology International 31:3, 289-300
CrossRef64
Rebecca D. Jackson, Nicole C. Wright, Thomas J. Beck, Duane Sherrill, Jane A. Cauley, Cora E. Lewis, Andrea Z. LaCroix, Meryl S. LeBoff, Scott Going, Tamsen Bassford, Zhao Chen. (2011) Calcium Plus Vitamin D Supplementation Has Limited Effects on Femoral Geometric Strength in Older Postmenopausal Women: The Women’s Health Initiative. Calcified Tissue International 88:3, 198-208
CrossRef65
Suruchi Khanna, Krishna K. Pillai, Divya Vohora. (2011) Bisphosphonates in phenytoin-induced bone disorder. Bone 48:3, 597-606
CrossRef66
José Manuel Quesada Gómez, Josep Blanch Rubió, Manuel Díaz Curiel, Adolfo Díez Pérez. (2011) Calcium Citrate and Vitamin D in the Treatment of Osteoporosis. Clinical Drug Investigation1
CrossRef67
S. Lee, P. Glendenning, C. A. Inderjeeth. (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, 741-753
CrossRef68
V. Rabenda, O. Bruyère, J.-Y. Reginster. (2011) Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporosis International 22:3, 893-901
CrossRef69
G. O’Malley, E. Mulkerrin. (2011) Vitamin D insufficiency: a common and treatable problem in the Irish population. Irish Journal of Medical Science 180:1, 7-13
CrossRef70
Khashayar Sakhaee, Naim M Maalouf, Rajiv Kumar, Andreas Pasch, Orson W Moe. (2011) Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney International 79:4, 393-403
CrossRef71
Rosen, Clifford J., . (2011) Vitamin D Insufficiency. New England Journal of Medicine 364:3, 248-254
Full Text72
Robert KR Scragg, Tim Kenealy, Linda Julia M Bryant, Carlos A Camargo Jr, Robert KR Scragg. 2011. Vitamin D for preventing cardiovascular disease. .
CrossRef73
Robert P. Heaney, Connie M. Weaver, Jeffrey Blumberg. (2011) EBN (Evidence-Based Nutrition) Ver. 2.0. Nutrition Today 46:1, 22-26
CrossRef74
V Benetou, P Orfanos, D Zylis, S Sieri, P Contiero, R Tumino, M C Giurdanella, P H M Peeters, J Linseisen, A Nieters, H Boeing, C Weikert, U Pettersson, I Johansson, H B Bueno-de-Mesquita, M Dorronsoro, P Boffetta, A Trichopoulou. (2011) Diet and hip fractures among elderly Europeans in the EPIC cohort. European Journal of Clinical Nutrition 65:1, 132-139
CrossRef75
Rowan T. Chlebowski, Karen C. Johnson, Dorothy Lane, Mary Pettinger, Charles L. Kooperberg, Jean Wactawski-Wende, Tom Rohan, Mary Jo O'Sullivan, Shagufta Yasmeen, Robert A. Hiatt, James M. Shikany, Mara Vitolins, Janu Khandekar, F. Allan Hubbell. (2011) 25-Hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. Maturitas 68:1, 73-78
CrossRef76
G. Leidig-Bruckner, H. J. Roth, T. Bruckner, A. Lorenz, F. Raue, K. Frank-Raue. (2011) Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels—an observational study during clinical practice conditions. Osteoporosis International 22:1, 231-240
CrossRef77
Evelien Gielen, Steven Boonen, Dirk Vanderschueren, Mieke Sinnesael, Annemieke Verstuyf, Frank Claessens, Koen Milisen, Sabine Verschueren. (2011) Calcium and Vitamin D Supplementation in Men. Journal of Osteoporosis 2011, 1-6
CrossRef78
Rowan T Chlebowski. (2011) Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Research 13:4, 217
CrossRef79
Joel E Michalek, Harry G Preuss, Harry A Croft, Patti L Keith, Samuel C Keith, Monika Dapilmoto, Nicholas V Perricone, Robert B Leckie, Gilbert R Kaats. (2011) Changes in total body bone mineral density following a common bone health plan with two versions of a unique bone health supplement: a comparative effectiveness research study. Nutrition Journal 10:1, 32
CrossRef80
Olivia I. Okereke, JoAnn E. Manson. 2011. The VITamin D and OmegA-3 TriaL (VITAL). , 2043-2055.
CrossRef81
Dwight A. Towler. 2011. Vitamin D. , 1403-1426.
CrossRef82
Aasis Unnanuntana, Brian J. Rebolledo, Joseph M. Lane. 2011. The Role of Vitamin D in Orthopedic Surgery. , 927-944.
CrossRef83
Bruce W. Hollis. 2011. Detection of Vitamin D and Its Major Metabolites. , 823-844.
CrossRef84
Heike Bischoff-Ferrari, Bess Dawson-Hughes. 2011. Relevance of Vitamin D Deficiency in Adult Fracture and Fall Prevention. , 1145-1153.
CrossRef85
Harald Sourij, Harald Dobnig. 2011. Vitamin D and Cardiovascular Disease. , 1973-1997.
CrossRef86
Peter R. Ebeling, John A. Eisman. 2011. Vitamin D and Osteoporosis. , 1129-1144.
CrossRef87
M. Kärkkäinen, M. Tuppurainen, K. Salovaara, L. Sandini, T. Rikkonen, J. Sirola, R. Honkanen, J. Jurvelin, E. Alhava, H. Kröger. (2010) Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65–71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International 21:12, 2047-2055
CrossRef88
Ahmad Nazrun Shuid, Sharlina Mohamad, Norazlina Mohamed, Fazalina Mohd Fadzilah, Sabarul Afian Mokhtar, Shahrum Abdullah, Faizah Othman, Farihah Suhaimi, Norliza Muhammad, Ima Nirwana Soelaiman. (2010) Effects of calcium supplements on fracture healing in a rat osteoporotic model. Journal of Orthopaedic Research 28:12, 1651-1656
CrossRef89
M. J. Bolland, A. Grey, G. D. Gamble, I. R. Reid. (2010) Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice 64:13, 1719-1722
CrossRef90
Véronique Rabenda, Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, 677-689
CrossRef91
T. P. Ip, J. Leung, A. W. C. Kung. (2010) Management of osteoporosis in patients hospitalized for hip fractures. Osteoporosis International 21:S4, 605-614
CrossRef92
C. Castelo-Branco, X. Cortés, M. Ferrer. (2010) Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric 13:6, 578-584
CrossRef93
Ian R Reid, Mark J. Bolland, Andrew Grey. (2010) Does calcium supplementation increase cardiovascular risk?. Clinical Endocrinology 73:6, 689-695
CrossRef94
Diane L Kamen, Jimmy D Alele. (2010) Skeletal manifestations of systemic autoimmune diseases. Current Opinion in Endocrinology, Diabetes and Obesity 17:6, 540-545
CrossRef95
V. Rabenda, J.-Y. Reginster. (2010) Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International 21:12, 1993-2002
CrossRef96
Mary Frances Picciano. (2010) Vitamin D Status and Health. Critical Reviews in Food Science and Nutrition 50:sup1, 24-25
CrossRef97
P. D. Miller, R. J. Derman. (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporosis International 21:11, 1793-1802
CrossRef98
Heikki Kröger, Matti Kärkkäinen, Risto Honkanen. (2010) Calcium and vitamin D in promotion of postmenopausal bone health. Women's Health 6:6, 773-776
CrossRef99
Stefan Pilz, Andreas Tomaschitz. (2010) Role of vitamin D in arterial hypertension. Expert Review of Cardiovascular Therapy 8:11, 1599-1608
CrossRef100
Lini Alappat, Michael Valerio, Atif B. Awad. (2010) Effect of vitamin D and β-sitosterol on immune function of macrophages. International Immunopharmacology 10:11, 1390-1396
CrossRef101
Anne B. Newman. (2010) An Overview of the Design, Implementation, and Analyses of Longitudinal Studies on Aging. Journal of the American Geriatrics Society 58, S287-S291
CrossRef102
Jim I. Mann. (2010) Evidence-based nutrition: Does it differ from evidence-based medicine?. Annals of Medicine 42:7, 475-486
CrossRef103
Cheryl D. Toner, Cindy D. Davis, John A. Milner. (2010) The Vitamin D and Cancer Conundrum: Aiming at a Moving Target. Journal of the American Dietetic Association 110:10, 1492-1500
CrossRef104
Rosen, Clifford J., Khosla, Sundeep, . (2010) Placebo-Controlled Trials in Osteoporosis — Proceeding with Caution. New England Journal of Medicine 363:14, 1365-1367
Full Text105
Jean H.M. Feyen, Georges Rawadi. 2010. Osteoporosis: Current and Future Anabolic Therapy. .
CrossRef106
Taison D. Bell, Marie B. Demay, Sherri-Ann M. Burnett-Bowie. (2010) The biology and pathology of vitamin D control in bone. Journal of Cellular Biochemistry 111:1, 7-13
CrossRef107
Paul Lips, Roger Bouillon, Natasja M. Van Schoor, Dirk Vanderschueren, Sabine Verschueren, Natalia Kuchuk, Koen Milisen, Steven Boonen. (2010) REVIEW ARTICLE: Reducing fracture risk with calcium and vitamin D. Clinical Endocrinology 73:3, 277-285
CrossRef108
Matthew C. Kostek, Joseph M. Devaney, Heather Gordish-Dressman, Tamara B. Harris, Paul D. Thompson, Priscilla M. Clarkson, Theodore J. Angelopoulos, Paul M. Gordon, Niall M. Moyna, Linda S. Pescatello, Paul S. Visich, Robert F. Zoeller, Richard L. Seip, Melissa Garcia, Rongling Li, Joseph M. Zmuda, Matthew J. Delmonico, Alka Kanaya, Eric P. Hoffman. (2010) A polymorphism near IGF1 is associated with body composition and muscle function in women from the Health, Aging, and Body Composition Study. European Journal of Applied Physiology 110:2, 315-324
CrossRef109
Jeffrey Blumberg, Robert P Heaney, Michael Huncharek, Theresa Scholl, Meir Stampfer, Reinhold Vieth, Connie M Weaver, Steven H Zeisel. (2010) Evidence-based criteria in the nutritional context. Nutrition Reviews 68:8, 478-484
CrossRef110
N. L. Waltman, J. J. Twiss, C. D. Ott, G. J. Gross, A. M. Lindsey, T. E. Moore, K. Berg, K. Kupzyk. (2010) The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporosis International 21:8, 1361-1369
CrossRef111
Barbara K. Dunn, Peter Greenwald. (2010) Cancer Prevention II: Introduction. Seminars in Oncology 37:4, 321-326
CrossRef112
M. Adnan Nadir, Benjamin R. Szwejkowski, Miles D. Witham. (2010) Vitamin D and Cardiovascular Prevention. Cardiovascular Therapeutics 28:4, e5-e12
CrossRef113
Suresh K. Nath, Robin K. Dutta. (2010) Enhancement of Limestone Defluoridation of Water by Acetic and Citric Acids in Fixed Bed Reactor. CLEAN - Soil, Air, Watern/a-n/a
CrossRef114
Sébastien Czernichow, Tao Fan, Gonzalo Nocea, Shuvayu Sankar Sen. (2010) Calcium and vitamin D intake by postmenopausal women with osteoporosis in France. Current Medical Research and Opinion 26:7, 1667-1674
CrossRef115
Helen L. Henry, Roger Bouillon, Anthony W. Norman, J. Christopher Gallagher, Paul Lips, Robert P. Heaney, Reinhold Vieth, John M. Pettifor, Bess Dawson-Hughes, Christel J. Lamberg-Allardt, Peter R. Ebeling. (2010) 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. The Journal of Steroid Biochemistry and Molecular Biology 121:1-2, 4-6
CrossRef116
H. A. Bischoff-Ferrari, A. Shao, B. Dawson-Hughes, J. Hathcock, E. Giovannucci, W. C. Willett. (2010) Benefit–risk assessment of vitamin D supplementation. Osteoporosis International 21:7, 1121-1132
CrossRef117
Kari Salovaara, Marjo Tuppurainen, Matti Kärkkäinen, Toni Rikkonen, Lorenzo Sandini, Joonas Sirola, Risto Honkanen, Esko Alhava, Heikki Kröger. (2010) Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: A population-based 3-year randomized, controlled trial-the OSTPRE-FPS. Journal of Bone and Mineral Research 25:7, 1487-1495
CrossRef118
Sheru Kansal, Linda Fried. (2010) Bone Disease in Elderly Individuals With CKD. Advances in Chronic Kidney Disease 17:4, e41-e51
CrossRef119
Susan Willis, Kay Thomas. (2010) DO ORAL CALCIUM SUPPLEMENTS INCREASE THE RISK OF UROLITHIASIS?. BJU International 106:2, 155-157
CrossRef120
Bruce W. Hollis. (2010) Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Endocrinology & Metabolism Clinics of North America 39:2, 271-286
CrossRef121
John Robbins. (2010) Vitamin D and the prevention of falls: has the time come?. Aging Health 6:3, 269-271
CrossRef122
JoAnn E. Manson, Matthew A. Allison, J. Jeffrey Carr, Robert D. Langer, Barbara B. Cochrane, Susan L. Hendrix, Judith Hsia, Julie R. Hunt, Cora E. Lewis, Karen L. Margolis, Jennifer G. Robinson, Rebecca J. Rodabough, Asha M. Thomas. (2010) Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause1
CrossRef123
Sherrie H. Kaplan, John Billimek, Dara H. Sorkin, Quyen Ngo-Metzger, Sheldon Greenfield. (2010) Who Can Respond to Treatment?. Medical Care 48, S9-S16
CrossRef124
Natalie Baecker, Petra Frings-Meuthen, Scott M. Smith, Martina Heer. (2010) Short-term high dietary calcium intake during bedrest has no effect on markers of bone turnover in healthy men. Nutrition 26:5, 522-527
CrossRef125
Gert J.D. Bergman, Tao Fan, Jeffrey T. McFetridge, Shuvayu S. Sen. (2010) Efficacy of vitamin D 3 supplementation in preventing fractures in elderly women: A meta-analysis. Current Medical Research and Opinion 26:5, 1193-1201
CrossRef126
Johann D. Ringe, John G. Doherty. (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatology International 30:7, 863-869
CrossRef127
Debby Uyl, Piet P. M. M. Geusens, Frank N. R. Berkum, Harry H. M. L. Houben, Max C. Jebbink, Willem F. Lems. (2010) Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clinical Rheumatology 29:5, 465-472
CrossRef128
Michael F. Holick, Joseph J. Lamb, Robert H. Lerman, Veera R. Konda, Gary Darland, Deanna M. Minich, Anuradha Desai, Tai C. Chen, Melissa Austin, Jacob Kornberg, Jyh-Lurn Chang, Alex Hsi, Jeffrey S. Bland, Matthew L. Tripp. (2010) Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. Journal of Bone and Mineral Metabolism 28:3, 342-350
CrossRef129
Matti K. Kärkkäinen, Marjo Tuppurainen, Kari Salovaara, Lorenzo Sandini, Toni Rikkonen, Joonas Sirola, Risto Honkanen, Jari Arokoski, Esko Alhava, Heikki Kröger. (2010) Does daily vitamin D 800IU and calcium 1000mg supplementation decrease the risk of falling in ambulatory women aged 65–71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas 65:4, 359-365
CrossRef130
Tuula Pekkarinen, Ville-Valtteri Välimäki, Stiina Aarum, Ursula Turpeinen, Esa Hämäläinen, Eliisa Löyttyniemi, Matti J Välimäki. (2010) The same annual dose of 292000 IU of vitamin D 3 (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D 3 concentrations and renal function. Clinical Endocrinology 72:4, 455-461
CrossRef131
Elaine D. Mackowiak, Yelena Bernstein, Stephen H. Paul. (2010) The Adult Vitamin and Mineral Supplement Maze. The Consultant Pharmacist 25:4, 234-240
CrossRef132
Jennifer E Isenor, Mary H. H Ensom. (2010) Is There a Role for Therapeutic Drug Monitoring of Vitamin D Level as a Surrogate Marker for Fracture Risk?. Pharmacotherapy 30:3, 254-264
CrossRef133
Patrice Fardellone, François-Emery Cotté, Christian Roux, Eric Lespessailles, Florence Mercier, Anne-Françoise Gaudin. (2010) Calcium intake and the risk of osteoporosis and fractures in French women. Joint Bone Spine 77:2, 154-158
CrossRef134
Jane A Cauley, Neeta Parimi, Kristine E Ensrud, Douglas C Bauer, Peggy M Cawthon, Steven R Cummings, Andrew R Hoffman, James M Shikany, Elizabeth Barrett-Connor, Eric Orwoll. (2010) Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. Journal of Bone and Mineral Research 25:3, 545-553
CrossRef135
Marlena C. Kruger, Linda M. Schollum, Barbara Kuhn-Sherlock, Andon Hestiantoro, Paulus Wijanto, Julie Li-Yu, Imelda Agdeppa, Joanne M. Todd, Richard Eastell. (2010) The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone 46:3, 759-767
CrossRef136
D. Ashley Hill, Michael Cacciatore, Georgine M. Lamvu. (2010) Electronic prescribing influence on calcium supplementation: a randomized controlled trial. American Journal of Obstetrics and Gynecology 202:3, 236.e1-236.e5
CrossRef137
Teun M. Post, Serge C.L.M. Cremers, Thomas Kerbusch, Meindert Danhof. (2010) Bone Physiology, Disease and Treatment. Clinical Pharmacokinetics 49:2, 89-118
CrossRef138
Mark J. Bolland, Andrew Grey. (2010) Benefits of Vitamin D?. The American Journal of Medicine 123:2, e17
CrossRef139
Kavitha K Reddy, Barbara A Gilchrest. (2010) What Is All This Commotion about Vitamin D?. Journal of Investigative Dermatology 130:2, 321-326
CrossRef140
Daniel G. Federman, Sarah A. Stechschulte, Robert S. Kirsner. (2010) The Reply. The American Journal of Medicine 123:2, e19
CrossRef141
Sunil M. Shah, Iain M. Carey, Tess Harris, Stephen DeWilde, Derek G. Cook. (2010) Calcium supplementation, cardiovascular disease and mortality in older women. Pharmacoepidemiology and Drug Safety 19:1, 59-64
CrossRef142
&NA;. (2010) Management of osteoporosis in postmenopausal women. Menopause 17:1, 25-54
CrossRef143
Jeremiah Miller, Richard L. Gallo. (2010) Vitamin D and innate immunity. Dermatologic Therapy 23:1, 13-22
CrossRef144
Dacia Cerdá Gabaroi, Pilar Peris, Ana Monegal, Carolina Albaladejo, Ma Ángels Martínez, África Muxí, Ma Jesús Martínez de Osaba, Xavier Surís, Núria Guañabens. (2010) Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17:1, 135-139
CrossRef145
Bodo Lehmann, Michael Meurer. (2010) Vitamin D metabolism. Dermatologic Therapy 23:1, 2-12
CrossRef146
L ARMAS. 2010. Calcium, Bone Strength and Fractures. , 235-241.
CrossRef147
R BOUILLON. 2010. Vitamin D and Bone. , 243-253.
CrossRef148
David Borradale, Michael Kimlin. (2009) Vitamin D in health and disease: an insight into traditional functions and new roles for the ‘sunshine vitamin’. Nutrition Research Reviews 22:02, 118
CrossRef149
Andrew Rosenzweig, Richa Mishra. (2009) Evaluation and management of osteoporosis and fragility fractures in the elderly. Aging Health 5:6, 833-850
CrossRef150
Jennifer L. Kelsey, Elizabeth J. Samelson. (2009) Variation in risk factors for fractures at different sites. Current Osteoporosis Reports 7:4, 127-133
CrossRef151
Meghan Bodenberg, Holly Byrnes. 2009. Nutraceuticals for Bone and Joint Diseases. , 253-275.
CrossRef152
Elena Segal, Chaim Zinman, Batia Raz, Sophia Ish-Shalom. (2009) Low patient compliance—A major negative factor in achieving vitamin D adequacy in elderly hip fracture patients supplemented with 800IU of vitamin D3 daily. Archives of Gerontology and Geriatrics 49:3, 364-367
CrossRef153
Muneaki Ishijima, Yuko Sakamoto, Makoto Yamanaka, Akifumi Tokita, Keiichiro Kitahara, Haruka Kaneko, Hisashi Kurosawa. (2009) Minimum Required Vitamin D Level for Optimal Increase in Bone Mineral Density with Alendronate Treatment in Osteoporotic Women. Calcified Tissue International 85:5, 398-404
CrossRef154
Kristina L. Penniston, Andrea N. Jones, Stephen Y. Nakada, Karen E. Hansen. (2009) Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women. BJU International 104:10, 1512-1516
CrossRef155
Sarah L Morgan. (2009) Nutrition and bone: it is more than calcium and vitamin D. Women's Health 5:6, 727-737
CrossRef156
Masako Himeno, Naoko Tsugawa, Akiko Kuwabara, Minori Fujii, Nobuko Kawai, Yuzuru Kato, Noriko Kihara, Tomoko Toyoda, Masami Kishimoto, Yoko Ogawa, Shoko Kido, Toshiaki Noike, Toshio Okano, Kiyoshi Tanaka. (2009) Effect of vitamin D supplementation in the institutionalized elderly. Journal of Bone and Mineral Metabolism 27:6, 733-737
CrossRef157
Stefan Pilz, Andreas Tomaschitz, Eberhard Ritz, Thomas R. Pieber. (2009) Vitamin D status and arterial hypertension: a systematic review. Nature Reviews Cardiology 6:10, 621-630
CrossRef158
José Sanfelix-Genovés, Vicente F. Gil-Guillén, Domingo Orozco-Beltran, Vicente Giner-Ruiz, Salvador Pertusa-Martínez, Begoña Reig-Moya, Concepción Carratalá. (2009) Determinant Factors of Osteoporosis Patientsʼ Reported Therapeutic Adherence to Calcium and/or Vitamin D Supplements. Drugs & Aging 26:10, 861-869
CrossRef159
R. Rizzoli, O. Bruyere, J. B. Cannata-Andia, J.-P. Devogelaer, G. Lyritis, J. D. Ringe, B. Vellas, J.-Y. Reginster. (2009) Management of osteoporosis in the elderly. Current Medical Research and Opinion 25:10, 2373-2387
CrossRef160
E. Michael Lewiecki. (2009) Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis. Journal of Women's Health 18:10, 1615-1626
CrossRef161
Miles D Witham, M Adnan Nadir, Allan D Struthers. (2009) Effect of vitamin D on blood pressure: a systematic review and meta-analysis. Journal of Hypertension 27:10, 1948-1954
CrossRef162
Martin A. Weinstock, Arnold M. Moses. (2009) Skin cancer meets vitamin D: The way forward for dermatology and public health. Journal of the American Academy of Dermatology 61:4, 720-724
CrossRef163
Silvina Levis, E Paul Cherniack, Hermes Florez, Bernard A Roos, Bruce R Troen. (2009) Vitamin D supplementation in older persons: benefits and requirements. Aging Health 5:5, 701-709
CrossRef164
R. T. Wilson, J. Wang, V. Chinchilli, J. P. Richie, J. Virtamo, L. E. Moore, D. Albanes. (2009) Fish, Vitamin D, and Flavonoids in Relation to Renal Cell Cancer Among Smokers. American Journal of Epidemiology 170:6, 717-729
CrossRef165
Y. Rolland, G. Abellan van Kan, A. Bénétos, H. Blain, M. Bonnefoy, P. Chassagne, C. Jeandel, M. Laroche, F. Nourhashémi, P. Orcel, F. Piette, C. Ribot, P. Ritz, C. Roux, J. Taillandier, F. Trémollières, G. Weryha, B. Vellas. (2009) Fragilité, ostéoporose et fracture du col du fémur: causes, conséquences et perspectives thérapeutiques. Les cahiers de l'année gérontologique 1:3, 172-187
CrossRef166
A. Avenell, J. A. Cook, G. S. MacLennan, G. C. McPherson. (2009) Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age and Ageing 38:5, 606-609
CrossRef167
Camil Castelo-Branco, Manel Ciria-Recasens, María J. Cancelo-Hidalgo, Santiago Palacios, Javier Haya-Palazuelos, Jordi Carbonell-Abelló, Josep Blanch-Rubió, María J. Martínez-Zapata, José Manasanch, Lluís Pérez-Edo. (2009) Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss. Menopause 16:5, 984-991
CrossRef168
Anne-Annette P. RASO, Sandra V. NAVARRA, Julie LI-YU, Tito P. TORRALBA. (2009) Survey of vitamin D levels among post-menopausal Filipino women with osteoporosis. International Journal of Rheumatic Diseases 12:3, 225-229
CrossRef169
C Palacios, KJ Joshipura, WC Willett. (2009) Nutrition and health: guidelines for dental practitioners. Oral Diseases 15:6, 369-381
CrossRef170
T. Constans, G. Deschasse, D. Chavanne. (2009) Indications et modalités de prescription de la vitamine D et du calcium. Les cahiers de l'année gérontologique 1:3, 196-200
CrossRef171
P Kilpinen-Loisa, H Pihko, U Vesander, A Paganus, U Ritanen, O Mäkitie. (2009) Insufficient energy and nutrient intake in children with motor disability. Acta Paediatrica 98:8, 1329-1333
CrossRef172
Karen E. Hansen. (2009) Osteoimmunology: Prevalence of hypovitaminosis D and relationship to fracture. Nature Reviews Rheumatology 5:8, 417-418
CrossRef173
Mark S. Nanes, Caleb B. Kallen. (2009) Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertility and Sterility 92:2, 403-412
CrossRef174
William D Fraser. (2009) Hyperparathyroidism. The Lancet 374:9684, 145-158
CrossRef175
Eric M. Matheson, Arch G. Mainous, Mark A. Carnemolla. (2009) The association between onion consumption and bone density in perimenopausal and postmenopausal non-Hispanic white women 50 years and older. Menopause 16:4, 756-759
CrossRef176
Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Clementina D. Ceria-Ulep, Barbara B. Cochrane, Dorothy S. Lane, Mindy Ginsberg, Sylvia Wassertheil-Smoller, David L. Page. (2009) A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Research and Treatment 116:2, 339-350
CrossRef177
Yuna Zhong, Catherine A. Okoro, Lina S. Balluz. (2009) Association of total calcium and dietary protein intakes with fracture risk in postmenopausal women: The 1999–2002 National Health and Nutrition Examination Survey (NHANES). Nutrition 25:6, 647-654
CrossRef178
Fadoua Allali, Sihame El Aichaoui, Hamza Khazani, Boubker Benyahia, Bouchra Saoud, Saâd El Kabbaj, Rachid Bahiri, Redouane Abouqal, Najia Hajjaj-Hassouni. (2009) High Prevalence of Hypovitaminosis D in Morocco: Relationship to Lifestyle, Physical Performance, Bone Markers, and Bone Mineral Density. Seminars in Arthritis and Rheumatism 38:6, 444-451
CrossRef179
Angela G. Juby. (2009) The challenges of interpreting efficacy of hip protector pads in fracture prevention in high-risk seniors. Clinical Rheumatology 28:6, 723-727
CrossRef180
Karl Michaelsson. (2009) The calcium quandary. Nutrition 25:6, 655-656
CrossRef181
Michael M. Altaweel, Robert P. Hanzlik, James N. Ver Hoeve, Janis Eells, Baoyan Zhang. (2009) Ocular and Systemic Safety Evaluation of Calcium Formate as a Dietary Supplement. Journal of Ocular Pharmacology and Therapeutics 25:3, 223-230
CrossRef182
Jean-Philippe Bonjour, Léon Guéguen, Cristina Palacios, Martin J. Shearer, Connie M. Weaver. (2009) Minerals and vitamins in bone health: the potential value of dietary enhancement. British Journal of Nutrition 101:11, 1581
CrossRef183
William B. Grant. (2009) The Health Benefits of Solar Irradiance and Vitamin D and the Consequences of Their Deprivation. Clinical Reviews in Bone and Mineral Metabolism 7:2, 134-146
CrossRef184
A. Z. LaCroix, J. Kotchen, G. Anderson, R. Brzyski, J. A. Cauley, S. R. Cummings, M. Gass, K. C. Johnson, M. Ko, J. Larson, J. E. Manson, M. L. Stefanick, J. Wactawski-Wende. (2009) Calcium Plus Vitamin D Supplementation and Mortality in Postmenopausal Women: The Women's Health Initiative Calcium-Vitamin D Randomized Controlled Trial. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 64A:5, 559-567
CrossRef185
, Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer. (2009) Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009. Wiener Medizinische Wochenschrift 159:S122, 1-34
CrossRef186
I. R. Reid, M. J. Bolland, A. Grey. (2009) Effect of calcium supplementation on hip fractures: reply to correspondence. Osteoporosis International 20:5, 835-836
CrossRef187
Erik Nordenström, Johan Westerdahl, Anders Bergenfelz. (2009) Effect on bone density of postoperative calcium and vitamin-D supplementation in patients with primary hyperparathyroidism: A retrospective study. Langenbeck's Archives of Surgery 394:3, 461-467
CrossRef188
Alison Avenell, William J Gillespie, Lesley D Gillespie, Dianne O'Connell, Alison Avenell. 2009. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. .
CrossRef189
Amy H. Warriner, Ryan C. Outman, Kenneth G. Saag, Sarah D. Berry, Cathleen Colón-Emeric, Kellie L. Flood, Kenneth W. Lyles, S Bobo Tanner, Nelson B. Watts, Jeffrey R. Curtis. (2009) Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture. Southern Medical Journal 102:4, 397-404
CrossRef190
Forrest Nielsen. 2009. Major Minerals—Calcium, Magnesium, and Phosphorus. , 193-218.
CrossRef191
Robert W. Lash, Jane M. Nicholson, Lourdes Velez, R. Van Harrison, Jane McCort. (2009) Diagnosis and Management of Osteoporosis. Primary Care: Clinics in Office Practice 36:1, 181-198
CrossRef192
Michael F. Holick. (2009) Vitamin D and Health: Evolution, Biologic Functions, and Recommended Dietary Intakes for Vitamin D. Clinical Reviews in Bone and Mineral Metabolism 7:1, 2-19
CrossRef193
Heike Bischoff-Ferrari. (2009) Vitamin D in Fracture Prevention and Muscle Function and Fall Prevention. Clinical Reviews in Bone and Mineral Metabolism 7:1, 107-112
CrossRef194
Karin B. Michels, Walter C. Willett. (2009) The Women’s Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Research and Treatment 114:1, 1-6
CrossRef195
Gwendolen Buhr, Connie W. Bales. (2009) Nutritional Supplements for Older Adults: Review and Recommendations—Part I. Journal of Nutrition For the Elderly 28:1, 5-29
CrossRef196
Kevin Y. Tse, Brandon R. Macias, R. Scott Meyer, Alan R. Hargens. (2009) Heritability of bone density: Regional and gender differences in monozygotic twins. Journal of Orthopaedic Research 27:2, 150-154
CrossRef197
Ego Seeman. (2009) To stop or not to stop, that is the question. Osteoporosis International 20:2, 187-195
CrossRef198
Margaret Rees. (2009) Alternative treatments for the menopause. Best Practice & Research Clinical Obstetrics & Gynaecology 23:1, 151-161
CrossRef199
M. Severo, C. Lopes, R. Lucas, H. Barros. (2009) Development of a tool for the assessment of calcium and vitamin D intakes in clinical settings. Osteoporosis International 20:2, 231-237
CrossRef200
Christian Roux, Karine Briot, Laure Gossec, Sami Kolta, Tilo Blenk, Dieter Felsenberg, David M. Reid, Richard Eastell, Claus C. Glüer. (2009) Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole. Calcified Tissue International 84:1, 13-19
CrossRef201
Guiyun Zhou, Jill Stoltzfus, Beth Ann Swan. (2009) Optimizing Vitamin D Status to Reduce Colorectal Cancer Risk: An Evidentiary Review. Clinical Journal of Oncology Nursing 13:4, E3-E17
CrossRef202
M. Rodríguez, B. Daniels, S. Gunawardene, G.K. Robbins. (2009) High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients. AIDS Research and Human Retroviruses 25:1, 9-14
CrossRef203
Akiko KUWABARA, Naoko TSUGAWA, Kiyoshi TANAKA, Minori FUJII, Nobuko KAWAI, Sachiko MUKAE, Yuzuru KATO, Yasuko KOJIMA, Kaori TAKAHASHI, Kazumasa OMURA, Reiko KAGAWA, Akira INOUE, Toshiaki NOIKE, Shoko KIDO, Toshio OKANO. (2009) Improvement of Vitamin D Status in Japanese Institutionalized Elderly by Supplementation with 800 IU of Vitamin D3. Journal of Nutritional Science and Vitaminology 55:6, 453-458
CrossRef204
T. Cederholm. 2009. Nutrition and bone health in the elderly. , 252-270.
CrossRef205
Olivier Bruyere, Caroline Decock, Melanie Delhez, Julien Collette, Jean-Yves Reginster. (2009) Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case–control study. Women's Health 5:1, 49-54
CrossRef206
Irene Hamrick, Sandra H. Counts. (2008) Vitamin and Mineral Supplements. Primary Care: Clinics in Office Practice 35:4, 729-747
CrossRef207
Bruce W Hollis. (2008) Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 489-494
CrossRef208
Wei-Bo XIA, Ling XU, Hua SU. (2008) Vitamin D deficiency and osteoporosis. International Journal of Rheumatic Diseases 11:4, 366-373
CrossRef209
R. T. Chlebowski, K. C. Johnson, C. Kooperberg, M. Pettinger, J. Wactawski-Wende, T. Rohan, J. Rossouw, D. Lane, M. J. O'Sullivan, S. Yasmeen, R. A. Hiatt, J. M. Shikany, M. Vitolins, J. Khandekar, F. A. Hubbell, . (2008) Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. JNCI Journal of the National Cancer Institute 100:22, 1581-1591
CrossRef210
C. Speers, P. Brown. (2008) Breast Cancer Prevention Using Calcium and Vitamin D: A Bright Future?. JNCI Journal of the National Cancer Institute 100:22, 1562-1564
CrossRef211
Anne E Wolff, Andrea N Jones, Karen E Hansen. (2008) Vitamin D and musculoskeletal health. Nature Clinical Practice Rheumatology 4:11, 580-588
CrossRef212
Samir Gupta. (2008) Colorectal Polyps: The Scope and Management of the Problem. The American Journal of the Medical Sciences 336:5, 407-417
CrossRef213
(2008) Vitamin D for prevention of chronic disease: the need for continued research. Internal Medicine Journal 38:11, 813-815
CrossRef214
Ian C Logan, Miles D Witham. (2008) Vitamin D in older people. Reviews in Clinical Gerontology 18:04, 287
CrossRef215
Zhao Chen, Jeffrey Stanaway. 2008. Calcium and Vitamin D in Aging Populations. , 103-112.
CrossRef216
René Rizzoli. (2008) Nutrition: its role in bone health. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 813-829
CrossRef217
David A Bushinsky, Justin Silver. (2008) Nutritional vitamin D: the benefits of supplementation. Current Opinion in Internal Medicine 7:5, 490-492
CrossRef218
Michael F Holick. (2008) Vitamin D: a D-Lightful health perspective. Nutrition Reviews 66, S182-S194
CrossRef219
Steven Boonen, Eddy Dejaeger, Dirk Vanderschueren, Katrien Venken, An Bogaerts, Sabine Verschueren, Koen Milisen. (2008) Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 765-785
CrossRef220
A.E. Kearns, D.F. Kallmes. (2008) Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement. American Journal of Neuroradiology 29:10, 1816-1822
CrossRef221
M. S. LeBoff, W. G. Hawkes, J. Glowacki, J. Yu-Yahiro, S. Hurwitz, J. Magaziner. (2008) Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporosis International 19:9, 1283-1290
CrossRef222
Diane L. Schneider. (2008) Management of osteoporosis in geriatric populations. Current Osteoporosis Reports 6:3, 100-107
CrossRef223
Robert L. Brunner, Barbara Cochrane, Rebecca D. Jackson, Joseph Larson, Cora Lewis, Marian Limacher, Milagros Rosal, Sally Shumaker, Robert Wallace. (2008) Calcium, Vitamin D Supplementation, and Physical Function in the Women's Health Initiative. Journal of the American Dietetic Association 108:9, 1472-1479
CrossRef224
Marcia Gene Ko. (2008) New thoughts about estrogen therapy from the Women’s Health Initiative. Current Osteoporosis Reports 6:3, 108-113
CrossRef225
Brett A. Freedman, Benjamin K. Potter, Leon J. Nesti, Jeffrey R. Giuliani, Chadwick Hampton, Timothy R. Kuklo. (2008) Osteoporosis and vertebral compression fractures—continued missed opportunities. The Spine Journal 8:5, 756-762
CrossRef226
Gideon M. Hirschfield, Teru Kumagi, E. Jenny Heathcote. (2008) Preventative hepatology: minimising symptoms and optimising care. Liver International 28:7, 922-934
CrossRef227
Mark G. Martens, Howard Shaw. (2008) Maximizing Effectiveness of Bisphosphonate Therapy for Osteoporosis. Southern Medical Journal 101:8, 824-830
CrossRef228
Ankur A Karnik, Joan M von Feldt. (2008) Osteoporosis in the elderly. Aging Health 4:4, 351-363
CrossRef229
P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky, R. E. Coleman, T. Guise, A. Lipton, M. Tubiana-Hulin. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Annals of Oncology 19:8, 1407-1416
CrossRef230
I. R. Reid, M. J. Bolland, A. Grey. (2008) Effect of calcium supplementation on hip fractures. Osteoporosis International 19:8, 1119-1123
CrossRef231
(2008) Thigh Pain After Total Hip Replacement. Orthopedics 31:7, 700-701
CrossRef232
Nicole K. Johnson, Timothy Clifford, Kelly M. Smith. (2008) Understanding Risk Factors, Screening, and Treatment of Postmenopausal Osteoporosis. Orthopedics 31:7, 676-680
CrossRef233
E. P. Cherniack, H. Florez, B. A. Roos, B. R. Troen, S. Levis. (2008) Hypovitaminosis D in the elderly: From bone to brain. The Journal of Nutrition Health and Aging 12:6, 366-373
CrossRef234
J. F. Aloia, S. Arunabh-Talwar, S. Pollack, J. K. Yeh. (2008) The remodeling transient and the calcium economy. Osteoporosis International 19:7, 1001-1009
CrossRef235
David A Bushinsky, Justin Silver. (2008) Nutritional vitamin D: the benefits of supplementation. Current Opinion in Nephrology and Hypertension 17:4, 345-347
CrossRef236
Rikke Andersen, Christian Mølgaard, Lene T. Skovgaard, Christine Brot, Kevin D. Cashman, Jette Jakobsen, Christel Lamberg-Allardt, Lars Ovesen. (2008) Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study. British Journal of Nutrition 100:01,
CrossRef237
AS Menon, AS Narula, AG Mathur. (2008) Multivitamins: Use or misuse?. Medical Journal Armed Forces India 64:3, 263-267
CrossRef238
William D. Leslie, Norine Miller, Linda Rogala, Charles N. Bernstein. (2008) Vitamin D Status and Bone Density in Recently Diagnosed Inflammatory Bowel Disease: The Manitoba IBD Cohort Study. The American Journal of Gastroenterology 103:6, 1451-1459
CrossRef239
Albert Parés, Núria Guañabens. (2008) Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment. Clinics in Liver Disease 12:2, 407-424
CrossRef240
Helen M. Macdonald, Alexandra Mavroeidi, Rebecca J. Barr, Alison J. Black, William D. Fraser, David M. Reid. (2008) Vitamin D status in postmenopausal women living at higher latitudes in the UK in relation to bone health, overweight, sunlight exposure and dietary vitamin D. Bone 42:5, 996-1003
CrossRef241
J. González Macías, N. Guañabens Gay, C. Gómez Alonso, L. del Río Barquero, M. Muñoz Torres, M. Delgado, L. Pérez Edo, J. Bernardino Díaz López, E. Jódar Gimeno, F. Hawkins Carranza. (2008) Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral. Revista Clínica Española 208, 1-24
CrossRef242
C. Roux, H. A. Bischoff-Ferrari, S. E. Papapoulos, A. E. de Papp, J. A. West, R. Bouillon. (2008) New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Current Medical Research and Opinion 24:5, 1363-1370
CrossRef243
Y. Rolland, G. Abellan Kan, A. Benetos, H. Blain, M. Bonnefoy, P. Chassagne, C. Jeandel, M. Laroche, F. Nourhashemi, P. Orcel, F. Piette, C. Ribot, P. Ritz, C. Roux, J. Taillandier, F. Tremollieres, G. Weryha, B. Vellas. (2008) Frailty, osteoporosis and hip fracture: Causes, consequences and therapeutic perspectives. The Journal of Nutrition Health and Aging 12:5, a319-a330
CrossRef244
J. W. Nieves, E. Barrett-Connor, E. S. Siris, M. Zion, S. Barlas, Y. T. Chen. (2008) Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporosis International 19:5, 673-679
CrossRef245
Eric L. Ding, Saurabh Mehta, Wafaie W. Fawzi, Edward L. Giovannucci. (2008) Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. International Journal of Cancer 122:8, 1690-1694
CrossRef246
Ross L. Prentice, Garnet L. Anderson. (2008) The Women's Health Initiative: Lessons Learned. Annual Review of Public Health 29:1, 131-150
CrossRef247
Natasha Khazai, Suzanne E. Judd, Vin Tangpricha. (2008) Calcium and vitamin D: Skeletal and extraskeletal health. Current Rheumatology Reports 10:2, 110-117
CrossRef248
Carolyn B Becker. (2008) Does supplementation with calcium alone or in combination with vitamin D reduce the risk of osteoporotic fracture?. Nature Clinical Practice Endocrinology & Metabolism 4:4, 190-191
CrossRef249
Kamilia Tai, Allan G. Need, Michael Horowitz, Ian M. Chapman. (2008) Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition 24:3, 279-285
CrossRef250
John R. Asplin. (2008) Evaluation of the Kidney Stone Patient. Seminars in Nephrology 28:2, 99-110
CrossRef251
Jordan L. Geller, John S. Adams. (2008) Vitamin D therapy. Current Osteoporosis Reports 6:1, 5-11
CrossRef252
Silvio Garattini, Vittorio Bertele’. (2008) Do we learn the right things from clinical trials?. European Journal of Clinical Pharmacology 64:2, 115-125
CrossRef253
Katherine H Noe, Sara LP Schrader. (2008) Bone health and antiseizure drugs: diagnosis and management. Aging Health 4:1, 75-84
CrossRef254
R. Rizzoli, S. Boonen, M.L. Brandi, N. Burlet, P. Delmas, J.Y. Reginster. (2008) The role of calcium and vitamin D in the management of osteoporosis. Bone 42:2, 246-249
CrossRef255
Moira A Petit, Thomas J Beck, Julie M Hughes, Hung-Mo Lin, Christy Bentley, Tom Lloyd. (2008) Proximal Femur Mechanical Adaptation to Weight Gain in Late Adolescence: A Six-Year Longitudinal Study. Journal of Bone and Mineral Research 23:2, 180-188
CrossRef256
Johanna T. Dwyer, Mary Frances Picciano, Joseph M. Betz, Kenneth D. Fisher, Leila G. Saldanha, Elizabeth A. Yetley, Paul M. Coates, John A. Milner, Jackie Whitted, Vicki Burt, Kathy Radimer, Jaimie Wilger, Katherine E. Sharpless, Joanne M. Holden, Karen Andrews, Janet Roseland, Cuiwei Zhao, Amy Schweitzer, James Harnly, Wayne R. Wolf, Charles R. Perry. (2008) Progress in developing analytical and label-based dietary supplement databases at the NIH Office of Dietary Supplements. Journal of Food Composition and Analysis 21, S83-S93
CrossRef257
Luigi Gennari, Giuseppe Martini. (2008) Does calcium supplementation reduce the risk of osteoporotic fracture and bone loss?. Nature Clinical Practice Rheumatology 4:2, 70-71
CrossRef258
N.M. van Schoor, M. Visser, S.M.F. Pluijm, N. Kuchuk, J.H. Smit, P. Lips. (2008) Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42:2, 260-266
CrossRef259
T. Winzenberg, G. Jones. (2008) Recommended Calcium Intakes in Children: Have We Set the Bar Too High?. IBMS BoneKEy 5:2, 59-68
CrossRef260
B.L. Clarke. (2008) Factors Associated With 5-Year Risk of Hip Fracture in Postmenopausal Women. Yearbook of Endocrinology 2008, 196-198
CrossRef261
G. Guardia, N. Parikh, T. Eskridge, E. Phillips, G. Divine, D. Sudhaker Rao. (2008) Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications. Osteoporosis International 19:1, 13-19
CrossRef262
R. M. Francis. (2008) What do we currently know about nutrition and bone health in relation to United Kingdom public health policy with particular reference to calcium and vitamin D?. British Journal of Nutrition 99:01,
CrossRef263
B.L. Clarke. (2008) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Yearbook of Endocrinology 2008, 208-210
CrossRef264
Krystallenia I. Alexandraki, Vassiliki Syriou, Panayiotis D. Ziakas, Nikolaos V. Apostolopoulos, Antonios I. Alexandrakis, Christina Piperi, Ekaterini Kavoulaki, Ioannis Myriokefalitakis, Georgios Korres, Evanthia Diamanti-Kandarakis. (2008) The knowledge of osteoporosis risk factors in a Greek female population. Maturitas 59:1, 38-45
CrossRef265
Shubham Pant, Charles L Shapiro. (2008) Aromatase Inhibitor-Associated Bone Loss. Drugs 68:18, 2591-2600
CrossRef266
Marci Goldstein Adams, Stacie Geller, Laura Studee. 2007. Menopause and Midlife. .
CrossRef267
Wendy Ward. 2007. Osteoporosis and Osteoarthritis. .
CrossRef268
Benjamin MP Tang, Guy D Eslick, Caryl Nowson, Caroline Smith, Alan Bensoussan. (2007) Calcium and vitamin D for prevention of osteoporotic fractures – Authors' reply. The Lancet 370:9605, 2099
CrossRef269
Ross L. Prentice. (2007) Observational studies, clinical trials, and the women’s health initiative. Lifetime Data Analysis 13:4, 449-462
CrossRef270
Rebecca D. Jackson, Shubhangi Shidham. (2007) The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: Lessons learned from the women’s health initiative. Current Osteoporosis Reports 5:4, 153-159
CrossRef271
Bess Dawson-Hughes, Heike A Bischoff-Ferrari. (2007) Therapy of Osteoporosis With Calcium and Vitamin D. Journal of Bone and Mineral Research 22:S2, V59-V63
CrossRef272
Wang, Rui, Lagakos, Stephen W., Ware, James H., Hunter, David J., Drazen, Jeffrey M., . (2007) Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials. New England Journal of Medicine 357:21, 2189-2194
Full Text273
J. D. Ringe, E. Schacht. (2007) Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatology International 28:2, 103-111
CrossRef274
(2007) Vitamin D Deficiency. New England Journal of Medicine 357:19, 1980-1982
Full Text275
Gayatri Gupta, Wilbert S. Aronow. (2007) Treatment of Postmenopausal Osteoporosis. Comprehensive Therapy 33:3, 114-119
CrossRef276
K. Rafferty, G. Walters, R.P. Heaney. (2007) Calcium Fortificants: Overview and Strategies for Improving Calcium Nutriture of the U.S. Population. Journal of Food Science 72:9, R152-R158
CrossRef277
Jane A Cauley, LieLing Wu, Nina S Wampler, Janice M Barnhart, Matthew Allison, Zhao Chen, Rebecca Jackson, John Robbins. (2007) Clinical Risk Factors for Fractures in Multi-Ethnic Women: The Women's Health Initiative. Journal of Bone and Mineral Research 22:11, 1816-1826
CrossRef278
Daniel Bunout, Gladys Barrera, María Pía de la Maza, Laura Leiva, Vivien Gattas, Sandra Hirsch. (2007) Height reduction, determined using knee height measurement as a risk factor or predictive sign for osteoporosis in elderly women. Nutrition 23:11-12, 794-797
CrossRef279
Sylvain Grenier. (2007) Vitamin D: Two indications for the price of one?. Canadian Pharmacists Journal 140:6, 390-394
CrossRef280
Jun Iwamoto, Tsuyoshi Takeda, Yoshihiro Sato. (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate. Expert Opinion on Pharmacotherapy 8:16, 2743-2756
CrossRef281
P. J. Ryan. (2007) Vitamin D therapy in clinical practice. One dose does not fit all. International Journal of Clinical Practice 61:11, 1894-1899
CrossRef282
Mishaela R. Rubin, Tanja Rundek, Donald J. McMahon, Hye-Seung Lee, Ralph L. Sacco, Shonni J. Silverberg. (2007) Carotid artery plaque thickness is associated with increased serum calcium levels: The Northern Manhattan study. Atherosclerosis 194:2, 426-432
CrossRef283
Faustino R. Pérez-López. (2007) Vitamin D and its implications for musculoskeletal health in women: An update. Maturitas 58:2, 117-137
CrossRef284
William B Grant. (2007) Roles of solar UV radiation and vitamin D in human health and how to obtain vitamin D. Expert Review of Dermatology 2:5, 563-577
CrossRef285
H. J. Teede, I. A. Jayasuriya, C. P. Gilfillan. (2007) Fracture prevention strategies in patients presenting to Australian hospitals with minimal-trauma fractures: a major treatment gap. Internal Medicine Journal 37:10, 674-679
CrossRef286
F. Jakob. (2007) Metabolische Knochenerkrankungen. Der Internist 48:10, 1101-1118
CrossRef287
Julie Glowacki. (2007) Vitamin D inadequacy in 2007: what it is and how to manage it. Current Opinion in Orthopaedics 18:5, 480-485
CrossRef288
Helena S. Salminen, Maria E. Sääf, Sven-Erik Johansson, Hans Ringertz, Lars-Erik Strender. (2007) The effect of transvaginal estradiol on bone in aged women: A randomised controlled trial. Maturitas 57:4, 370-381
CrossRef289
Jean-Yves Reginster. (2007) Calcium and vitamin D for osteoporotic fracture risk. The Lancet 370:9588, 632-634
CrossRef290
O. Bruyère, O. Malaise, A. Neuprez, J. Collette, J.
Y. Reginster. (2007) Prevalence of vitamin D inadequacy in European postmenopausal women. Current Medical Research and Opinion 23:8, 1939-1944
CrossRef291
Gary C. Curhan. (2007) Epidemiology of Stone Disease. Urologic Clinics of North America 34:3, 287-293
CrossRef292
Benjamin MP Tang, Guy D Eslick, Caryl Nowson, Caroline Smith, Alan Bensoussan. (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. The Lancet 370:9588, 657-666
CrossRef293
Holick, Michael F., . (2007) Vitamin D Deficiency. New England Journal of Medicine 357:3, 266-281
Full Text294
Beate Lanske, M Shawkat Razzaque. (2007) Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Current Opinion in Nephrology and Hypertension 16:4, 311-318
CrossRef295
Allan Lipton, Michael Gnant, Matti Aapro. (2007) Managing aromatase inhibitor-associated bone loss in breast cancer. Women's Health 3:4, 441-448
CrossRef296
Roberta B. Ness, James S. Koopman, Mark S. Roberts. (2007) Causal System Modeling in Chronic Disease Epidemiology: A Proposal. Annals of Epidemiology 17:7, 564-568
CrossRef297
Miguel Gallego, Eugenio Berlanga, Marta Larrosa. (2007) Osteoporosis in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 14:4, 191-196
CrossRef298
. (2007) Calcium met vitamine D en heupfracturen. Huisarts en Wetenschap 50:7, 527-528
CrossRef299
S. M. Chatfield, C. Brand, P. R. Ebeling, D. M. Russell. (2007) Vitamin D deficiency in general medical inpatients in summer and winter. Internal Medicine Journal 37:6, 377-382
CrossRef300
Panagiota N. Mitrou, Demetrius Albanes, Stephanie J. Weinstein, Pirjo Pietinen, Philip R. Taylor, Jarmo Virtamo, Michael F. Leitzmann. (2007) A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). International Journal of Cancer 120:11, 2466-2473
CrossRef301
Sydney Bonnick, Susan Broy, Fran Kaiser, Carol Teutsch, Elizabeth Rosenberg, Paul DeLucca, Mary Melton. (2007) Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Current Medical Research and Opinion 23:6, 1341-1349
CrossRef302
Nico C. Geurs. (2007) Osteoporosis and periodontal disease. Periodontology 2000 44:1, 29-43
CrossRef303
John A. Sunyecz, Richard Derman. (2007) Update on the Use of Bisphosphonates in the Management of Postmenopausal Osteoporosis by Obstetricians-Gynecologists. Obstetrical & Gynecological Survey 62:6, 407-416
CrossRef304
E. Tsiridis, Z. Gamie, P.G. Conaghan, P.V. Giannoudis. (2007) Biological options to enhance periprosthetic bone mass. Injury 38:6, 704-713
CrossRef305
Diane Nykamp, Edie D. Kavanaugh, Amy P. Wenker. (2007) <b>Vitamins: The Wise Choice for Women with Cardiovascular Disease</b>. The Consultant Pharmacist 22:6, 490-502
CrossRef306
Khosla, Sundeep, Melton, L. Joseph III, . (2007) Osteopenia. New England Journal of Medicine 356:22, 2293-2300
Full Text307
Kent Wehmeier. 2007. Nutrition and Fracture Risk. , 511-536.
CrossRef308
Gilberto Gonz??lez, Jos?? N. Alvarado, Auristela Rojas, Carlos Navarrete, Carmen G. Vel??squez, Eugenio Arteaga. (2007) High prevalence of vitamin D deficiency in Chilean healthy postmenopausal women with normal sun exposure. Menopause 14:3, 455-461
CrossRef309
Peter M. Wayne, Douglas P. Kiel, David E. Krebs, Roger B. Davis, Jacqueline Savetsky-German, Maureen Connelly, Julie E. Buring. (2007) The Effects of Tai Chi on Bone Mineral Density in Postmenopausal Women: A Systematic Review. Archives of Physical Medicine and Rehabilitation 88:5, 673-680
CrossRef310
Leon Speroff. (2007) The future of postmenopausal hormone therapy: It's time to move forward. Maturitas 57:1, 103-106
CrossRef311
R. A. Lyons, A. Johansen, S. Brophy, R. G. Newcombe, C. J. Phillips, B. Lervy, R. Evans, K. Wareham, M. D. Stone. (2007) Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International 18:6, 811-818
CrossRef312
E. Seeman, J. Compston, J. Adachi, M. L. Brandi, C. Cooper, B. Dawson-Hughes, B. Jönsson, H. Pols, J. A. Cramer. (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis International 18:6, 711-719
CrossRef313
Caroline Bolton-Smith, Marion ET McMurdo, Colin R Paterson, Patricia A Mole, Julia M Harvey, Steven T Fenton, Celia J Prynne, Gita D Mishra, Martin J Shearer. (2007) Two-Year Randomized Controlled Trial of Vitamin K1 (Phylloquinone) and Vitamin D3 Plus Calcium on the Bone Health of Older Women. Journal of Bone and Mineral Research 22:4, 509-519
CrossRef314
G. Duque. (2007) As a Matter of Fat: New Perspectives on the Understanding of Age-Related Bone Loss. International Bone and Mineral Society Knowledge Environment 4:4, 129-140
CrossRef315
E. Seeman. (2007) Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents. Osteoporosis International 18:5, 569-573
CrossRef316
A. A. Fisher, M. W. Davis. (2007) Calcium-PTH-vitamin D axis in older patients with hip fracture. Osteoporosis International 18:5, 693-695
CrossRef317
P. Garnero, F. Munoz, E. Sornay-Rendu, P.D. Delmas. (2007) Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 40:3, 716-722
CrossRef318
José A. Riancho, José L. Pérez-Castrillón, Carmen Valero, Jesús González-Macías. (2007) Ingesta de calcio insuficiente y fractura de cadera. Medicina Clínica 128:9, 355
CrossRef319
Gustavo Duque, Louise Mallet, Ayanna Roberts, Serge Gingrass, Richard Kremer, Louis-Georges Sainte-Marie, Douglas P. Kiel. (2007) To Treat or Not To Treat, That Is the Question: Proceedings of the Quebec Symposium for the Treatment of Osteoporosis in Long-Term Care Institutions, Saint-Hyacinthe, Quebec, November 5, 2004. Journal of the American Medical Directors Association 8:3, e67-e73
CrossRef320
Heike A. Bischoff-Ferrari. (2007) The 25-hydroxyvitamin D threshold for better health. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 614-619
CrossRef321
Robert P. Heaney. (2007) The case for improving vitamin D status. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 635-641
CrossRef322
H. A. Bischoff-Ferrari. (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporosis International 18:4, 401-407
CrossRef323
J. C. Pressley, B. Barlow, L. Quitel, A. Jafri. (2007) Improving Access to Comprehensive Injury Risk Assessment and Risk Factor Reduction in Older Adult Populations. American Journal of Public Health 97:4, 676-678
CrossRef324
Carrie Tompkins Stricker. (2007) Endocrine Effects of Breast Cancer Treatment. Seminars in Oncology Nursing 23:1, 55-70
CrossRef325
Richard Keen. (2007) Osteoporosis: strategies for prevention and management. Best Practice & Research Clinical Rheumatology 21:1, 109-122
CrossRef326
Diane L Schneider. (2007) Vitamin D and skeletal health. Current Opinion in Internal Medicine 6:1, 38-45
CrossRef327
Robert P Heaney. (2007) Evidence-based medicine and common sense: practical and ethical issues in clinical trials for osteoporosis. Future Rheumatology 2:1, 105-110
CrossRef328
B.L. Clarke. (2007) Calcium plus Vitamin D Supplementation and the Risk of Fractures. Yearbook of Endocrinology 2007, 342-343
CrossRef329
Michael F Holick. (2007) Optimal Vitamin D Status for the Prevention and Treatment of Osteoporosis. Drugs & Aging 24:12, 1017-1029
CrossRef330
Daisuke Inoue. (2007) Current and future prospects for anti-osteoporotic drugs. Folia Pharmacologica Japonica 130:3, 206-209
CrossRef331
P. Ferrari, R. Piazza, N. Ghidini, M. Bisi, G. Galizia, G. Ferrari. (2007) Lithiasis and Risk Factors. Urologia Internationalis 79:1, 8-15
CrossRef332
Elizabeth Tran, Barbara Demmig-Adams. (2007) Vitamins and minerals: powerful medicine or potent toxins?. Nutrition & Food Science 37:1, 50-60
CrossRef333
Robert P Heaney. (2007) Does daily calcium supplementation reduce the risk of clinical fractures in elderly women?. Nature Clinical Practice Rheumatology 3:1, 18-19
CrossRef334
Alexandra Papaioannou, Courtney C Kennedy, Lisa Dolovich, Elaine Lau, Jonathan D Adachi. (2007) Patient Adherence to Osteoporosis Medications. Drugs & Aging 24:1, 37-55
CrossRef335
Steven Boonen, Jean-Marc Kaufman, Stefan Goemaere, Roger Bouillon, Dirk Vanderschueren. (2007) The diagnosis and treatment of male osteoporosis: Defining, assessing, and preventing skeletal fragility in men. European Journal of Internal Medicine 18:1, 6-17
CrossRef336
2006. Contribution of Dairy Foods to Health throughout the Life Cycle. , 339-399.
CrossRef337
2006. Dairy Foods and Bone Health. , 181-244.
CrossRef338
Gail C. Davis, Terri L. White, Asphodel Yang. (2006) A bone health intervention for older adults living in residential settings. Research in Nursing & Health 29:6, 566-575
CrossRef339
Masoud Solaymani–Dodaran, Tim R. Card, Guruprasad P. Aithal, Joe West. (2006) Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study. Gastroenterology 131:6, 1752-1757
CrossRef340
Andrea L. Sikon, Holly L. Thacker, John Carey, Chad Deal, Angelo A. Licata. (2006) Secondary Osteoporosis: Are We Recognizing It?. Journal of Women's Health 15:10, 1174-1183
CrossRef341
Jean E Mulder, Nikheel S Kolatkar, Meryl S LeBoff. (2006) Drug Insight: existing and emerging therapies for osteoporosis. Nature Clinical Practice Endocrinology & Metabolism 2:12, 670-680
CrossRef342
Tim Green, C. Murray Skeaff. (2006) Does the vitamin D status of Australians and New Zealanders need improving and how do we do it?. Nutrition & Dietetics 63:4, 196-198
CrossRef343
Robert P Heaney. (2006) Evidence-based medicine and common sense: practical and ethical issues in clinical trials for osteoporosis. Future Rheumatology 1:6, 693-698
CrossRef344
Suzanne Oparil. (2006) Women and Hypertension. Cardiology in Review 14:6, 267-275
CrossRef345
&NA;. (2006) The role of calcium in peri- and postmenopausal women. Menopause 13:6, 862-877
CrossRef346
María Teresa del Campo, Pilar Aguado. (2006) Vitamina D: en busca de su umbral óptimo. Medicina Clínica 127:17, 651-652
CrossRef347
Ronald Tamler, Jeffrey I Mechanick. (2006) Dietary supplements and nutraceuticals in the management of endocrine disorders. Current Opinion in Endocrinology and Diabetes 13:5, 425-430
CrossRef348
Robin M. Daly, Shona Bass, Caryl Nowson. (2006) Long-term effects of calcium–vitamin-D3-fortified milk on bone geometry and strength in older men. Bone 39:4, 946-953
CrossRef349
Mary A. Gerend, Mindy J. Erchull, Leona S. Aiken, Jon K. Maner. (2006) Reasons and risk: Factors underlying women's perceptions of susceptibility to osteoporosis. Maturitas 55:3, 227-237
CrossRef350
Laura B Hansen. (2006) Osteoporosis update: effective prevention and treatment. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, 525-540
CrossRef351
Serge Ferrari, Ego Seeman, Gordon J Strewler. (2006) Clinical and basic research papers – September 2006 selections. BoneKEy-Osteovision 3:10, 1-6
CrossRef352
Gustavo Duque, Louise Mallet, Ayanna Roberts, Serge Gingrass, Richard Kremer, Louis-Georges Sainte-Marie, Douglas P. Kiel. (2006) To Treat or Not To Treat, That Is the Question: Proceedings of the Quebec Symposium for the Treatment of Osteoporosis in Long-Term Care Institutions, Saint-Hyacinthe, Quebec, November 5, 2004. Journal of the American Medical Directors Association 7:7, 435-441
CrossRef353
Michael F. Holick. (2006) The role of vitamin D for bone health and fracture prevention. Current Osteoporosis Reports 4:3, 96-102
CrossRef354
L. A. Lammers. (2006) Calcium plus vitamine-D-suppletie en de kans op fracturen. Medisch-Farmaceutische Mededelingen 44:9, 255-255
CrossRef355
S. Scharla. (2006) Stellenwert von nativem und biologisch aktivem Vitamin D bei der Prävention und Therapie der Osteoporose. Zeitschrift für Rheumatologie 65:5, 391-399
CrossRef356
Melissa J. Benton, Andrea White. (2006) Osteoporosis: Recommendations for Resistance Exercise and Supplementation With Calcium and Vitamin D to Promote Bone Health. Journal of Community Health Nursing 23:4, 201-211
CrossRef357
Tori Hudson. (2006) Women's Health Update. Alternative and Complementary Therapies 12:4, 187-189
CrossRef358
Benjamin K. Canales, Susan M. Leonard, Jasvinder A. Singh, Irene M. Orzano, Bernard Zimmermann, Derek Weiland, Manoj Monga, Hollis E. Krug. (2006) Spondyloarthropathy: An Independent Risk Factor for Kidney Stones. Journal of Endourology 20:8, 542-546
CrossRef359
Gary R. Lichtenstein, Bruce E. Sands, Michael Pazianas. (2006) Prevention and Treatment of Osteoporosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 12:8, 797-813
CrossRef360
Christopher B. Granger, John J.V. McMurray. (2006) Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology 48:3, 434-437
CrossRef361
Daniel Bunout, Gladys Barrera, Laura Leiva, Vivien Gattas, María Pía de la Maza, Marcelo Avendaño, Sandra Hirsch. (2006) Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Experimental Gerontology 41:8, 746-752
CrossRef362
Nick Alexander, Sylvia Rowe. (2006) Can Nutrition Research Change Its Mind?. Nutrition Today 41:4, 185-188
CrossRef363
Chin Lee, Darcy S. Majka. (2006) Is Calcium and Vitamin D Supplementation Overrated?. Journal of the American Dietetic Association 106:7, 1032-1034
CrossRef364
Sergio Ragi-Eis, Cristiano A.F. Zerbini, José R. Provenza, Luiz H.M. Griz, Luiz H. de Gregório, Luis A.T. Russo, Nilzio A. Silva, João L.C. Borges, Antonio C.A. de Souza, Marize L. Castro, E. Michael Lewiecki. (2006) Is It Ethical to Use Placebos in Osteoporosis Trials?. Journal of Clinical Densitometry 9:3, 274-280
CrossRef365
Jack Challem. (2006) Medical Journal Watch: Context and Applications. Alternative and Complementary Therapies 12:3, 143-146
CrossRef366
Philip Sambrook, Cyrus Cooper. (2006) Osteoporosis. The Lancet 367:9527, 2010-2018
CrossRef367
David Hosking. (2006) Are calcium supplements necessary in vitamin-D-replete individuals?. Nature Clinical Practice Endocrinology & Metabolism 2:6, 310-311
CrossRef368
S. BOONEN, D. VANDERSCHUEREN, P. HAENTJENS, P. LIPS. (2006) Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. Journal of Internal Medicine 259:6, 539-552
CrossRef369
M. J. Barger-Lux. (2006) Calcium, Vitamin D, and Fractures in the WHI Data. International Bone and Mineral Society Knowledge Environment 3:6, 19-21
CrossRef370
(2006) Calcium plus Vitamin D and the Risk of Fractures. New England Journal of Medicine 354:21, 2285-2287
Full Text371
E. Seeman. (2006) Hot stuff—can’t get enough. Osteoporosis International 17:6, 791-794
CrossRef372
&NA;. (2006) Management of osteoporosis in postmenopausal women. Menopause 13:3, 340-367
CrossRef373
N. M. Schmitt, W. Kirch. (2006) Besonderheiten der Pharmakotherapie bei Frauen im Alter. Der Gynäkologe 39:5, 367-372
CrossRef374
Joyce A. Generali. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:5, 484-486
CrossRef375
Robert Kleta. (2006) A key stone cop regulates oxalate homeostasis. Nature Genetics 38:4, 403-404
CrossRef376
(2006) Journal club. Kidney International 69:7, 1110-1111
CrossRef377
Philip E Lee, Janet E McElhaney, Larry Dian. (2006) Calcium and vitamin D supplementation for the prevention of fractures in postmenopausal women. Aging Health 2:2, 241-243
CrossRef378
Meredith Wadman. (2006) Failed prevention trials leave behind bounty of samples. Nature Medicine 12:4, 371-371
CrossRef379
Serge Ferrari, Ego Seeman, Gordon J Strewler. (2006) Clinical and basic research papers – February 2006 selections. BoneKEy-Osteovision 3:3, 1-4
CrossRef380
Finkelstein, Joel S., . (2006) Calcium plus Vitamin D for Postmenopausal Women — Bone Appétit?. New England Journal of Medicine 354:7, 750-752
Full Text381
Wactawski-Wende, Jean, Kotchen, Jane Morley, Anderson, Garnet L., Assaf, Annlouise R., Brunner, Robert L., O'Sullivan, Mary Jo, Margolis, Karen L., Ockene, Judith K., Phillips, Lawrence, Pottern, Linda, Prentice, Ross L., Robbins, John, Rohan, Thomas E., Sarto, Gloria E., Sharma, Santosh, Stefanick, Marcia L., Van Horn, Linda, Wallace, Robert B., Whitlock, Evelyn, Bassford, Tamsen, Beresford, Shirley A.A., Black, Henry R., Bonds, Denise E., Brzyski, Robert G., Caan, Bette, Chlebowski, Rowan T., Cochrane, Barbara, Garland, Cedric, Gass, Margery, Hays, Jennifer, Heiss, Gerardo, Hendrix, Susan L., Howard, Barbara V., Hsia, Judith, Hubbell, F. Allan, Jackson, Rebecca D., Johnson, Karen C., Judd, Howard, Kooperberg, Charles L., Kuller, Lewis H., LaCroix, Andrea Z., Lane, Dorothy S., Langer, Robert D., Lasser, Norman L., Lewis, Cora E., Limacher, Marian C., Manson, JoAnn E., . (2006) Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. New England Journal of Medicine 354:7, 684-696
Full Text382
Reynold Spector, Elliot S. Vesell. (2006) The Heart of Drug Discovery and Development: Rational Target Selection. Pharmacology 77:2, 85-92
CrossRef383
Eric J MacLaughlin, Rebecca B Sleeper, Danny McNatty, Cynthia L Raehl. (2006) Management of age-related osteoporosis and prevention of associated fractures. Therapeutics and Clinical Risk Management 2:3, 281-295
CrossRef384
Alison Avenell, William J Gillespie, Lesley D Gillespie, Dianne O'Connell, Alison Avenell. 2005. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. .
CrossRef
- Letters
